1184_CSP 5.0 1 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Phase I Study of APR -246 in Combination with Venetoclax and Azacitidine in 
TP53 -Mutant Myeloid Malignancies  
 
Protocol No.:  A19-11184   
IND No.:  139738   
  
Sponsor:  Aprea Therapeutics, Inc.  
 
 
  
Responsible Medical Officer:  Eyal C. Attar, M.D.  
  
Medical Monitor:    
 
 
 
 
  
Protocol Version:  5.0 
 
Replaces:  
 4.0 / 28 September 2020  
Date:  28 October 2021  
 
 
 
 
 
 
 
CONFIDENTIAL  
 
This document contains strictly confidential information and cannot be disclosed or 
used, unless authorized in writing by Aprea Therapeutics.   

1184_CSP 5.0 2 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
 Name:    Telephone:   
     
Address:      
     
Signature:    Date:   
 
   
Sponsor/Representative:  
 
S  
 INVESTIGATOR’S STATEMENT  
1. I have carefully read this protocol entitled “Phase I Study of APR -246 in Combination with 
Venetoclax and Azacitidine in TP53 -Mutant Myeloid Malignancies” and agree that it 
contains all the necessary information required to conduct the study. I agree to co nduct 
this study as outlined in the protocol.  
2. I understand that this study will not be initiated without approval of the appropriate 
Institutional Review Committee/Independent Ethics Committee (IRB/IEC), and that all 
administrative requirements of the g overning body of the Institution will be complied with 
fully.  
3. Informed written consent will be obtained from all participants in accordance with 
institutional guidelines, FDA requirements as specified in Title 21 CFR, Part 50, the 
European Union Directi ve 2001/20/EC and its associated Detailed Guidances, European 
Union GCP Directive 2005/28/EC, the International Counsel for Harmonisation (ICH) 
Guideline for Good Clinical Practice (GCP), Section 4.8, and the terms of the Declaration of 
Helsinki (2013).  
4. I will enroll participants who meet the protocol criteria for entry.  
5. I understand that my signature on each completed Case Report Form (CRF) indicates that 
I have carefully reviewed the complete set of CRFs and accept full responsibility for the 
conten ts thereof.  
6. I understand that the information presented in this study protocol is confidential, and I 
hereby assure that no information based on the conduct of the study will be released 
without prior consent from the Sponsor unless this requirement is superseded by the 
Food and Drug Administration (FDA), a Competent Authority of the European Union or 
another Regulatory Authority.  
 
Protocol Version 5.0: 28 October 2021  

1184_CSP 5.0 3 of 103 28 Octo ber 202 1 
Confidential - Entire Page  TABLE OF CONTENTS  
         Page No.  
 
INVESTIGATOR’S STATEMENT  ................................ ................................ ................................ .. 2 
TABL E OF CONTENTS  ................................ ................................ ................................ ...............  3 
CLINICAL STUDY SYNOPSIS  ................................ ................................ ................................ ..... 8 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ........  19 
1.0 GENERAL INFORMATION  ................................ ................................ .........................  23 
1.1 Protocol Number and Title of the Study  ................................ ................................ ...... 23 
1.2 Sponsor  ................................ ................................ ................................ ...........................  23 
1.3 Monitor  ................................ ................................ ................................ ............................  23 
1.4 Signature Authorization  ................................ ................................ ................................  23 
2.0 BACKGROUND INFORMATION  ................................ ................................ ................  24 
2.1 Introduction  ................................ ................................ ................................ ....................  24 
2.1.1  Acute Myeloid Leukemia  ................................ ................................ ...................  24 
2.1.2  TP53  Mutations in Myel oid Malignancies  ................................ ........................  24 
2.2 APR-246 ................................ ................................ ................................ ...........................  25 
2.3 Venetoclax  ................................ ................................ ................................ .......................  25 
2.4 Azacitidine  ................................ ................................ ................................ .......................  26 
2.5 Combination of Venetoclax with Azacitidine  ................................ ..............................  27 
2.6 APR-246 Preclinical Studies  ................................ ................................ ...........................  27 
2.6.1  Pharmacology and Mode of Action  ................................ ................................ . 27 
2.6.2  Safety Pharmacology ................................ ................................ .........................  28 
2.6.3  Pharmacokinetics and Metabolism in Animals  ................................ ..............  29 
2.6.4  Toxicology  ................................ ................................ ................................ ...........  30 
2.7 APR-246 Clinical Studies  ................................ ................................ ................................  31 
2.7.1  Phase I/II Study in Solid and Hematological Malignancies  ...........................  31 
2.7.2  Phase I/II Study in TP53 -Mutant Advanced Ovarian Cancer  .........................  31 
2.7.3  Phase I/Ib Study in Refractory Hematologic Malignancies  ...........................  32 
2.7.4  Phase Ib/II Study in TP53 -Mutant Myeloid Neoplasms  ................................ . 33 
2.7.5  Phase III Multicenter, Randomized, Open Label Study of APR -246 in 
Combination with Azacitidine  ................................ ................................ ......................  33 
2.7.6  APR-246 CNS Safety Overview  ................................ ................................ .........  33 
2.7.7  APR-246 Cardiac Safety Overview  ................................ ................................ .... 33 
2.8 Dose Rationale for APR -246 in Combination with Venetoclax and/or Azacitidine  . 35 
2.8.1  APR-246 and Azacitidine  ................................ ................................ ...................  35 
2.8.2  Venetoclax and Azacitidine  ................................ ................................ ...............  35 
2.8.3  Venetoclax and APR -246 ................................ ................................ ...................  35 
2.8.4  Expansion Cohorts in Front Line AML  ................................ .............................  36 
1184_CSP 5.0 4 of 103 28 Octo ber 202 1 
Confidential - Entire Page  2.9 Potential Ri sks and Benefits  ................................ ................................ ..........................  37 
2.9.1  Potential Risks  ................................ ................................ ................................ .... 37 
2.9.2  Potential Benefits  ................................ ................................ ..............................  38 
2.10  Characteristics of a Well -Conducted Trial  ................................ ................................ ... 38 
2.11  Patie nt Population  ................................ ................................ ................................ .........  39 
3.0 TRIAL OBJECTIVES AND PURPOSE  ................................ ................................ ...........  39 
4.0 TRIAL DESIGN  ................................ ................................ ................................ ............  40 
4.1 Overview of Trial Design  ................................ ................................ ................................  40 
4.2 End of Study  ................................ ................................ ................................ ....................  43 
4.3 Drug Products  ................................ ................................ ................................ .................  43 
4.3.1  APR-246 ................................ ................................ ................................ ...............  43 
4.3.2  Venetoclax  ................................ ................................ ................................ ..........  43 
4.3.3  Azacitidine  ................................ ................................ ................................ ..........  44 
4.4 Duration of Therapy ................................ ................................ ................................ ....... 44 
4.5 Trial Discontinuation  ................................ ................................ ................................ ...... 45 
4.6 Drug Accountability/Disposition of Clinical Trial Supplies  ................................ .........  45 
4.7 Registration  ................................ ................................ ................................ .....................  45 
5.0 SELECTION AND WITHDRAWAL OF PATIENTS  ................................ .......................  46 
5.1 Inclusion Criteria for Patients in Safety Lead -In Cohorts  ................................ ...........  46 
5.2 Exclusion Criteria for Patients in Safety Lead -In Cohorts  ................................ ..........  46 
5.3 Inclusion Criteria for Patients in Expansion Cohorts  ................................ .................  47 
5.4 Exclusion Criteria for Patients in Expansion Cohorts  ................................ ................  47 
5.5 Inclusion of Women, Minorities and Children  ................................ ............................  48 
5.6 Withdrawal Criteria  ................................ ................................ ................................ ........  48 
5.6.1  Study Treatment Discontinuation  ................................ ................................ ... 48 
5.6.2  Study Completion  ................................ ................................ ..............................  49 
5.6.3  Withdrawn Patients  ................................ ................................ ...........................  49 
5.7 Noncompliance  ................................ ................................ ................................ ..............  49 
6.0 TREATMENT OF PATIENTS  ................................ ................................ ........................  49 
6.1 Drug Preparation and Administration  ................................ ................................ .........  49 
6.1.1  APR-246 ................................ ................................ ................................ ...............  49 
6.1.2  Venetoclax  ................................ ................................ ................................ ..........  50 
6.1.3  Azacitidine  ................................ ................................ ................................ ..........  50 
6.1.4  Dose -Limiting Toxicity  ................................ ................................ .......................  51 
6.1.5  Recommended Phase II D ose (RP2D)  ................................ ..............................  52 
6.2 Dose Interruptions/Withholding  ................................ ................................ ..................  52 
6.3 Supportive Management  ................................ ................................ ...............................  53 
6.3.1  APR-246 ................................ ................................ ................................ ...............  53 
6.3.2  Management of CNS Adverse Events  ................................ ..............................  54 
6.3.3  Management of Nausea and Vomiting  ................................ ...........................  55 
6.3.4  Management of Infusion Reactions  ................................ ................................  56 
1184_CSP 5.0 5 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6.3.5  Management of Infection and/or Infestation Event(s)  ................................ .. 56 
6.3.6  Management of Neutropenia with or without Fever  ................................ .... 57 
6.3.7 APR-246 Dose Modification in the Setting of Moderate Renal Impairment  57 
6.3.8  Venetoclax Dose Adjustments  ................................ ................................ .........  57 
6.3.9  Azacitidine Dose Adjustments  ................................ ................................ .........  58 
6.3.10  Antifungal Prophylaxis  ................................ ................................ ......................  58 
6.4 Concomitant Treatment  ................................ ................................ ................................  58 
6.5 Monitoring Patient Complianc e ................................ ................................ ....................  59 
7.0 STUDY EVALUATIONS  ................................ ................................ ...............................  59 
7.1 Schedule of Study Evaluations  ................................ ................................ ......................  59 
7.2 Pre-Study Assessments  ................................ ................................ ................................ . 65 
7.2.1  Screening  ................................ ................................ ................................ ............  65 
7.2.2  Cycle 1  ................................ ................................ ................................ .................  66 
7.2.3  Cycle 2 Day 1 ±3 Day and Onwards (Cycle 3+)  ................................ ...............  68 
7.2.4  End of Odd Numbered Cycles  ................................ ................................ ..........  70 
7.2.5  End of Even Number ed Cycles  ................................ ................................ .........  70 
7.3 End of Treatment Visit  ................................ ................................ ................................ ... 70 
7.4 Long -Term Follow -Up ................................ ................................ ................................ .... 70 
8.0 STUDY ASSESSMENTS  ................................ ................................ ...............................  71 
8.1 Safety Assessments  ................................ ................................ ................................ ....... 71 
8.1.1  Safety Analysis  ................................ ................................ ................................ ... 71 
8.1.2  Reporting of Adverse Events  ................................ ................................ ............  71 
8.2 Efficacy Assessments  ................................ ................................ ................................ ..... 75 
8.2.1  Complete Remission Rate  ................................ ................................ .................  75 
8.2.2  Duration of Response  ................................ ................................ .......................  75 
8.2.3  Overall Response Rate  ................................ ................................ ......................  75 
8.2.4  Overall Survival  ................................ ................................ ................................ .. 75 
8.2.5  Stem Cell Transplant  ................................ ................................ .........................  75 
8.3 Progression -Free Survival (PFS)  ................................ ................................ ....................  75 
8.4 Pharmacokinetics  ................................ ................................ ................................ ...........  75 
8.5 Electrocardiographic Assessment  ................................ ................................ ................  77 
8.6 TP53  Testing  ................................ ................................ ................................ ....................  78 
9.0 STATISTICS  ................................ ................................ ................................ .................  78 
9.1 Sample Size  ................................ ................................ ................................ .....................  78 
9.2 Analysis Populations  ................................ ................................ ................................ ...... 79 
9.3 Endpoints  ................................ ................................ ................................ ........................  79 
9.3.1  Primary  ................................ ................................ ................................ ...............  79 
9.3.2  Secondary  ................................ ................................ ................................ ...........  79 
9.3.3  Exploratory  ................................ ................................ ................................ .........  80 
9.4 Safety  ................................ ................................ ................................ ...............................  80 
9.5 Efficacy  ................................ ................................ ................................ .............................  80 
9.6 Pharmacokinetic Analysis ................................ ................................ ..............................  81 
1184_CSP 5.0 6 of 103 28 Octo ber 202 1 
Confidential - Entire Page  9.7 Exploratory analyses  ................................ ................................ ................................ ...... 81 
10.0  QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES  ............................  82 
10.1  Monitoring of the Study and Regulatory Compliance  ................................ ................  82 
10.2  Curricula Vitae and Financial Disclosure of Investigators  ................................ .........  82 
10.3  Protocol Modifications  ................................ ................................ ................................ ... 82 
10.4  Publication Policy  ................................ ................................ ................................ ...........  82 
11.0  ETHICAL CONSIDERATIONS  ................................ ................................ .....................  83 
11.1  Informed Consent  ................................ ................................ ................................ ..........  83 
11.2  Institutional Review Board/Independent Ethics Committee  ................................ ..... 83 
11.3  Patient Privacy  ................................ ................................ ................................ ................  83 
12.0  DATA HANDLING AND RECORD KEEPING  ................................ ..............................  83 
12.1  Data to be Entered Directly in the Case Report Form ................................ ................  83 
12.2  Recording of Data  ................................ ................................ ................................ ..........  84 
12.3  Study Records  ................................ ................................ ................................ .................  84 
13.0  REFERENCES  ................................ ................................ ................................ ..............  85 
APPENDIX I – Response Criteria Based on Modified Recommendations of the 
International Working Group for Diagnosis, Standardization of Response Criteria, 
Treatment Outcomes, and Reporting Standards in Acute Myeloid Leukemia59 ...........  91 
APPENDIX II - Cockcroft -Gault Equation  ................................ ................................ .............  93 
APPENDIX III - ECOG Performance Status  ................................ ................................ ...........  94 
APPENDIX IV - Acceptable Contraceptive Methods  ................................ ...........................  95 
APPENDIX V - New York Heart Association (NYHA) Classification  ................................ .. 97 
APPENDIX VI - Study Drug Diaries  ................................ ................................ ........................  98 
APPENDIX VII - Patient Handout: Prohibited Medications (For Patients Enrolled in 
Cohorts wit h Venetoclax)  ................................ ................................ ................................ ... 100  
APPENDIX VIII  - Dose Modifications for Use with CYP3A and P -gp Inhibitors  ..............  102  
 
List of In -text Tables  
Table 1. Study Treatment and Prior Therapy by Cohort  ................................ ..............................  8 
Table 2. APR -246 Dose Levels  ................................ ................................ ................................ ....... 41 
Table 3. Study Treatment and Prior Therapy by Cohort  ................................ ............................  41 
Table 4. Management of CNS Adverse Events (Dizziness, Dyskinesia and Ataxia)  .................  55 
Table 5. Medications for Managements of Nausea and Vomiting  ................................ ............  55 
Table 6. Recommendations for prevention and treatment of cancer -related infections  ...... 56 
Table 7: APR-246 Dose Modification in the Setting of Moderate Renal Impairment  ..............  57 
Table 8: Study Calendar  ................................ ................................ ................................ .................  60 
Table 9. PK Blood Sampling Timepoints for APR -246 ................................ ................................ . 76 
Table 10 . PK Blood Sampling Timepoints for Venetoclax in Cycle 1  ................................ .........  76 
1184_CSP 5.0 7 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Table 11 . PK Blood Sampling Timepoints for Venetoclax in Cycles 2 -5 ................................ ... 77 
Table 12. ECG Assessment Requirements  ................................ ................................ ...................  77 
Table 13. CYP3A Inhibitors and Inducers 1 ................................ ................................ .................  103  
 
List of In -text Figures  
Figure 1. Dose -Finding Study Design  ................................ ................................ ..............................  9 
Figure 2. Structure of  APR-246 ................................ ................................ ................................ ...... 25 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 8 of 103 28 Octo ber 202 1 
Confidential - Entire Page  CLINICAL STUDY SYNOPSIS  
Title  Phase I of APR -246 in Combination with Venetoclax and/or Azacitidine in Myeloid 
Malignancies  
Sponsor  Aprea Therapeutics  
Monitor/Contr
act Research 
Organization 
(CRO)   
Number of 
Study Centers  Multicenter  
Clinical Phase  I 
Investigational 
Agent  APR-246 
Study Design  This clinical trial is a Phase I, open -label, dose -finding and cohort expansion study to 
determine the safety and preliminary efficacy of APR -246 in combination with 
venetoclax and/or azacitidine in patients with myeloid malignancies. The study 
includes a safety lead -in dose -finding portion followed by expansion portion ( Table 
1).  
Table 1. Study Treatment and Prior Therapy by Cohort  
Cohort  Disease  Study 
Treatment  Prior Therapy Permitted  
   VEN  HMA  LDAC  APR -
246 SCT IC 
Safety Lead -In Cohorts  
Cohort 
1 F/L AML  APR-246 + 
VEN no ≥1 prior for 
MDS 
required  no no yes for 
MDS  no 
Cohort 
2 F/L AML  APR-246 + 
VEN + AZA  no no no no no no 
Expansion Cohorts  
Cohort 
1 F/L AML  APR-246 + 
VEN no yes for 
MDS  no no yes for 
MDS  no 
Cohort 
2 F/L AML  APR-246 + 
VEN + AZA  no no no no no no 
Cohort 
3 R/R AML  APR-246 + 
VEN yes yes yes yes for 
MDS  yes yes 
Cohort 
4 R/R AML  APR-246 + 
VEN + AZA  yes no no yes for 
MDS  yes ≤1 prior  
Cohort 
5 F/L AML  APR-246 + 
AZA no no no no no no 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 9 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Abbreviations: AZA = azacitidine; F/L = front line; HMA = hypomethylating agent; IC = intensive chemotherapy; 
LDAC = low -dose cytarabine; MDS = myelodysplastic syndrome; R/R = refractory or relapsed; SCT = stem cell 
transplant; VEN = venetoclax  
During the safety lead -in portion of the study, two parallel cohorts will independently 
enroll patients following a 3 + 3 design, as outlined in Figure 1.  
 
 
Figure 1. Dose -Finding Study Design  
Dose -finding study design will be applied to each cohort of the safety lead -in portion 
(Figure 1). Each cohort will enroll up to a maximum of 6 patients. Dose -limiting 
toxicity (DLT) will be assessed after three patients have been enrolled in respective 
cohort and the last enrolled patien t has completed the 4 -week safety assessment 
period (i.e., one cycle of combination regimen). A patient that discontinues therapy 
during Cycle 1 without DLT is considered evaluable for the purpose of safety only if 
at least 80% of scheduled doses of APR -246 in combination with venetoclax with and 
without azacitidine were administered in the first cycle. At the first dose level of 4.5 
g/day of APR -246, if ≤1 patient out of 3 experiences a DLT, 3 additional patients will 
be enrolled. If ≤1 patient out of 6 ex periences DLT, the dose level (4.5 g/day of 
APR-246) will be deemed the recommended Phase II dose (RP2D) for that cohort. If 
≥2 patients out of the total 3 – 6 patients in the cohort experience DLT, the study will 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 10 of 103 28 Octo ber 202 1 
Confidential - Entire Page  continue enrollment at Dose Level -1 (4.0 g/day of APR -246). If ≤1 patient out of 6 
experiences DLT at this dose level, the dose level (4.0 g/day of APR -246) will be 
deemed the RP2D for that cohort. If ≥2 patients out of the total 3 – 6 patients at that 
dose level experience DLT, the study will co ntinue enrollment at Dose Level -2 (3.5 
g/day of APR -246). If ≤1 patient out of 6 experiences DLT at this dose level, the dose 
level (3.5 g/day of APR -246) will be deemed the RP2D for that cohort. If ≥2 patients 
out of the total 3 – 6 patients at this dose  level experience DLT, no additional patients 
will be enrolled at this dose. The trial will be halted, and the Data Review Team (DRT) 
will consider potential future dosing modifications.  
 
The expansion portion will begin once the recommended Phase II dose (RP2D) of 
APR-246 in combination with venetoclax and  azacitidine has been determined in 
order to assess the antitumor activity of these combinations. Approximately 70 
patients with TP53 -mutant myeloid malignancies will be enrolled in up to five cohort s, 
as outlined in Table 1. 
 
The two Data Review Meetings (DRMs) to assess Safety Lead -in Cohort 2 were held 
on 27 February 2020 (first cohort of 3 patie nts in Cohort 2) and 26 June 2020 (second 
cohort of 3 patients at Dose Level 1 in Cohort 2). After review of the 6 patients with 
AML treated for at least 1 cycle with the combination of APR -246, venetoclax, and 
azacitidine,  it was concluded by the DRT that  no DLTs were observed, and that the 
RP2D of APR -246 in this combination is 4.5 g/day.  
 
The two DRMs to assess Safety Lead -in Cohort 1 were held on 17 March 2020 and 7 
August 2020 . After review of the 6 patients with AML treated for at least 1 cycle with 
the combination of APR -246 and venetoclax, it was concluded by the DRT that no 
DLTs were observed, and that the RP2D of APR -246 in this combination is 4.5 g/day.  
Study 
Objectives  Primary objective: To evaluate the safety and tolerability of administration of 
APR-246 in combination with venetoclax and/or azacitidine in patients with 
TP53 -mutant myeloid malignancies.  
 
Secondary objectives:  
1. To assess the clinical activity o f APR -246 in combination with venetoclax 
and/or azacitidine in patients with myeloid malignancies by determination of 
complete remission (CR) rate.  
2. To assess the clinical activity of APR -246 in combination with venetoclax 
and/or azacitidine in patients wit h myeloid malignancies by determination of 
CR plus complete remission with incomplete hematologic recovery (CRi) rate.  
3. To assess the clinical activity of APR -246 in combination with venetoclax 
and/or azacitidine in patients with myeloid malignancies by de termination of 
CR plus complete remission with partial hematologic recovery (CRh) rate.  
4. To assess the clinical activity of APR -246 in combination with venetoclax 
and/or azacitidine in patients with myeloid malignancies by determination of 
overall response rate (ORR).  
5. To assess the clinical activity of APR -246 in combination with venetoclax 
and/or azacitidine in patients with AML by determination of progression -free 
survival (PFS).  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 11 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6. To assess the clinical activity of APR -246 in combination with venetoclax 
and/or azacitidine in patients with AML by determination of transition rate to 
hematopoietic stem cell transplant (HSCT).  
7. To assess the clinical activity of APR -246 in combination wi th venetoclax 
and/or azacitidine in patients with AML by determination of overall survival 
(OS).  
8. To assess clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with AML by determining the rate of red blood cell 
(RBC) a nd/or platelet transfusion independence (TI) for at least 56 days.  
9. To determine the pharmacokinetic profile of APR -246 and venetoclax.  
 
Exploratory objectives:  
1. To investigate molecular biomarkers for response prediction and disease 
monitoring in baseline and serial bone marrow or blood samples.  
Study 
Endpoints  Primary endpoints:  
1. DLTs, classified and graded according to the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events (NCI CTCAE, version 5.0).  
2. Frequency of treatment -emergent adverse events (TEAEs), and serious 
adverse events (SAEs) related to APR -246 in combination with venetoclax 
and/or azacitidine during the trial.  
3. The RP2D of APR -246 (the dose at which <2 out of 6 patients experience 
dose -limiting toxicity during t he safety assessment period).  
 
Secondary endpoints:  
1. CR rate, defined as the proportion of patients who achieve CR.  
2. CR + CRi rate, defined as the proportion of patients who achieve CR or CRi.  
3. CR + CRh rate, defined as the proportion of patients who achieve CR or CRh.  
4. Overall response rate (ORR), defined as the proportion of patients achieving 
CR, complete remission with incomplete hematologic recovery (CRi), 
complete remission with incomplete platelet recovery (CRp), partial 
remission (PR) and morpho logic leukemia -free state (MLFS) by the IWG 2003 
criteria ( APPENDIX I ). The complete remission with partial hematologic 
recovery (CRh) rate will also be determined and is defined as bone marrow 
blasts <5%, ANC >0.5 × 109/L and platelets >50 × 109/L. 
5. Overall survival (OS), measured from the date of initiating study treatment to 
the date of death. Patients who have not died by the analysis data cut -off 
date will be censored at their last date of contact.  
6. Rate of red blood cell  (RBC) and/or platelet transfusion independence (TI) for 
at least 56 days.  
7. Progression -free survival (PFS), defined from the date of initiating study 
treatment to the date of disease progression or death as a result of any 
cause.  
8. Proportion of patients who  transition to HSCT.  
9. Pharmacokinetic parameters: maximum concentration (C max), area under 
curve (AUC), V d and clearance (CL) of APR -246 and time of maximum 
concentration (T max), C max and AUC of venetoclax.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 12 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Exploratory endpoints:  
1. Exploratory molecular anal yses may include, but are not limited to: TP53  VAF 
by NGS, p53 immunohistochemistry  (IHC) , mutations in other genes by NGS, 
RNA expression.  
 
Eligibility 
Criteria for 
Patients in 
Safety Lead -In 
Cohorts  Inclusion Criteria : 
1. Signed informed consent form (ICF) and ability to comply with protocol 
requirements.  
2. Documented diagnosis of initial or relapsed AML according to World Health 
Organization (WHO) classification.  
3. Adequate organ function as defined by the following laboratory values:  
a. Creatinine clearanc e >30 mL/min (by Cockcroft -Gault method; 
APPENDIX II ), 
b. Total serum bilirubin <1.5 × ULN unless due to Gilbert’s syndrome, 
leukemic organ involvement, hemolysis or considered an effect of 
regular blood transfusions,  
c. Alanin e aminotransferase (ALT) and aspartate aminotransferase (AST) 
<3 × ULN, unless due to leukemic organ involvement.  
4. Age ≥18 years at the time of signing the ICF.  
5. At least one TP53  mutation which is not benign or likely benign . 
6. Eastern Cooperative Oncology Gr oup (ECOG) performance status of 0, 1 or 2 
(APPENDIX III ). 
7. Projected life expectancy of ≥12 weeks.  
8. Negative serum or urine pregnancy test prior to study treatment initiation in 
female patients of childbearing potential.  
9. Females of childbearing potential and males with female partners of 
childbearing potential must be willing to use an effective form of 
contraception such as latex condom, hormonal birth control, intrauterine 
device or double barrier method ( APPENDIX IV ) during chemotherapy 
treatment and for at least six months thereafter.  
 
Exclusion Criteria : 
1. Prior treatment for TP53 -mutant acute myeloid leukemia (AML) not permitted 
per Table 1. 
2. Known history of human immunodeficiency virus (HIV) or active hepatitis B 
or active hepatitis C infection.  
3. Any of the following cardiac abnormalities:  
a. Myocardial infarction within six months prior to registration;  
b. New York Heart Association Class III or IV ( APPENDIX V ) heart failure or 
known left ventricular ejection fraction (LVEF) <40%;  
c. A history of familial long QT syndrome;  
d. Symptomatic atrial or ventricular arrhythmias not controlled by 
medications;  
e. QTcF ≥470 msec, unless due to underlying bundle branch block and/or 
pacemaker and with approval of the medical monitor.  
4. Concomitant malignancies for which patients are receiving active therapy at 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 13 of 103 28 Octo ber 202 1 
Confidential - Entire Page  the time of signi ng consent. For example, patients with adequately treated 
basal or squamous cell carcinoma of the skin, adequately treated carcinoma 
in situ  (e.g. cervix), or breast cancer receiving adjuvant endocrine therapy may 
enroll irrespective of the time of diagnos is with Medical Monitor approval.  
5. Known active CNS involvement from AML. A diagnostic lumbar puncture is 
not required in the absence of suspicion for CNS disease.  
6. Malabsorption syndrome or other condition that precludes enteral route of 
administration.  
7. Pregnancy or lactation.  
8. Active uncontrolled systemic infection (viral, bacterial or fungal).  
Eligibility 
Criteria for 
Patients in 
Expansion 
Cohorts  Inclusion Criteria : 
1. Signed ICF and ability to comply with protocol requirements.  
2. Newly diagnosed or R/R AML according to WHO classification  with permitted 
prior therapy, as per Table 1. For patients with newly diagnosed AML bone 
marr ow and/or blood evidence of AML with ≥20% blasts is required. For 
patients with newly diagnosed AML, prior therapy with HMA and/or any 
chemotherapeutic agent for MDS is excluded.  
3. Adequate organ function as defined by the following laboratory values:  
a. Creatinine clearance >30 mL/min (by Cockcroft -Gault method; 
APPENDIX II ), 
b. Total serum bilirubin <1.5 × ULN unless due to Gilbert’s syndrome, 
leukemic organ involvement, hemolysis or considered an effect of 
regular blood t ransfusions,  
c. ALT and AST <3 × ULN, unless due to leukemic organ involvement.  
4. Age ≥18 years at the time of signing the ICF.  
5. At least one TP53  mutation which is not benign or likely benign , based on 
central TP53  testing results. If local TP53  mutation and/or p53 IHC results 
become available before central TP53 mutation results, enrollment may be 
made based on local results with Medical Monitor approval.  
6. ECOG performance status of 0, 1 or 2 ( APPENDIX III ). 
7. Projected life expectancy of ≥12 weeks.  
8. Negative serum pregnancy test prior to study treatment initiation in female 
patients of childbearing potential.  
9. Females of childbearing potential and males with female partners of 
childbearing potential must be willin g to use an effective form of 
contraception such as latex condom, hormonal birth control, intrauterine 
device or double barrier method ( APPENDIX IV ) during chemotherapy 
treatment and for at least six months thereafter.  
Exclusion Criteria : 
1. Known history of myeloproliferative neoplasm (MPN) (i.e., polycythemia vera, 
essential thrombocythemia and primary myelofibrosis are excluded).  
2. Known history of HIV or active hepatitis B or active hepatitis C infection.  
3. Any of the followi ng cardiac abnormalities:  
a. Myocardial infarction within six months prior to registration,  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 14 of 103 28 Octo ber 202 1 
Confidential - Entire Page  b. New York Heart Association Class III or IV ( APPENDIX V ) heart failure 
or known left ventricular ejection fraction (LVEF) <40%,  
c. A history of familial long QT syndrome,  
d. Symptomatic atrial or ventricular arrhythmias not controlled by 
medications,  
e. QTcF ≥470 msec, unless due to underlying bundle branch block 
and/or pacemaker and with approval of the medical monitor.  
4. Concomitant malignancies for which patients are receiving active therapy at 
the time of signing consent. For example, patients with adequately resected 
basal or squamous cell carcinoma of the skin, adequately resected carcinoma 
in situ  (e.g. cervix), or br east cancer receiving adjuvant endocrine therapy may 
enroll irrespective of the time of diagnosis with Medical Monitor approval.  
5. Prior exposure to anticancer therapies including chemotherapy, 
radiotherapy or other investigational therapy, including targete d small 
molecule agents within 14 days of the first day of study treatment  or within 
5 half -lives prior to first dose of study treatment.  
6. Prior exposure to biologic agents (e.g. monoclonal antibodies) for 
anti-neoplastic intent within 14 days prior to firs t dose of study drug.  
7. Known active CNS involvement from AML. A diagnostic lumbar puncture is 
not required in the absence of suspicion for CNS disease.  
8. Malabsorption syndrome or other condition that precludes enteral route of 
administration.  
9. Pregnancy or la ctation.  
10. Active uncontrolled systemic infection (viral, bacterial or fungal).  
Treatment 
Plan  Treatment may be administered on an outpatient basis. No investigational or 
commercial agents or therapies other than those described below may be 
administered with the intent to treat the patient's disease. Hydroxyurea may be used 
for control of leukocytosis.  
The study includes a safety lead -in dose -finding portion followed by the expansion 
portion, as outlined in Table 1. During the safety lead -in portion of the study, two 
cohorts will independently enroll patients following a 3 + 3 design.  
• Safety lead -in cohort 1 will enroll patients with TP53 -mutant AML, who have 
received at least one prior HMA regimen for MDS. These p atients will receive 
APR-246 at 4.5 g/day on days 1 –4 of each 28 -day cycle administered 
concurrently with venetoclax given orally at the dose of 400 mg daily.  
• Safety lead -in cohort 2 will enroll patients with previously untreated 
TP53 -mutant AML. These pat ients will receive APR -246 at 4.5 g/day on days 
1–4 administered concurrently with venetoclax given orally at the dose of 400 
mg daily and with azacitidine at the standard dose of 75 mg/m2 over 7 
consecutive days as a subcutaneous injection or IV infusion,  on days 1 –7 of 
each 28 -day cycle.  
 
Each cohort will enroll up to 6 patients. For dose -finding strategy please consult Study 
Design section of the Clinical Study Synopsis.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 15 of 103 28 Octo ber 202 1 
Confidential - Entire Page  The expansion portion will begin once the RP2D of APR -246 in combination with 
venet oclax and/or azacitidine has been determined in order to assess the antitumor 
activity of these combinations. Approximately 70 patients with  TP53 -mutant myeloid 
malignancies will be enrolled in up to five cohorts, as outlined in Table 1. 
 
In each portion, patients may continue treatment as long as toxicity remains 
acceptable and the patient has not withdrawn consent. Response  will be assessed 
based on the International Workin g Group (IWG) AML response criteria ( APPENDIX I ) 
after every treatment cycle the first year, then every two cycles.  
Duration of 
Follow -Up  
 Patients will be followed as per the Study Calendar . After a patient is removed or 
withdrawn from study treatment, the patient will be followed until death or 
withdrawal of consent for study participation.  
Off-treatment data on overall survival will be upd ated every month (i.e. every 28 days 
±3 days ) or until death or withdrawal of consent for study participation, whichever 
occurs first. If a patient is removed from the study due to unacceptable adverse 
events (AEs), the event(s) will be followed until resolution or stabilization of the 
adverse event. Patients who respond and discontinue study treatment for reasons 
other than PD should have response assessments and survival should be collected 
every month until relapse, death or withdrawal of consent for  study participation, 
whichever occurs first. After relapse, data for survival should be collected every 
month  (i.e. every 28 days ±3 days ) until death or withdrawal of consent for study 
participation, whichever occurs first.  
Criteria for Removal from Stud y Treatment  
Study treatment can continue for patients receiving clinical benefit, unless one or 
more withdrawal criteria are met, or at the patient’s discretion, or if the study is 
terminated.  
1. Study Treatment Discontinuation  
Study treatment must be dis continued if:  
• Evidence of disease progression. Patients who have relapsed or progressive 
disease but who are continuing to derive clinical benefit in the opinion of the 
investigator may continue to receive study treatment.  
• A patient becomes pregnant.  
• A patient is significantly non -compliant with the requirements of the 
protocol.  
• A patient has an adverse experience that would, in the Investigator’s 
judgment, make continued participation in the study an unacceptable risk.  
• The patient starts ne w treatment for their underlying disease.  
2. Patient Withdrawal from Study Treatment  
If the patient is permanently withdrawn from study treatment, but does not 
withdraw consent from the Study, the Investigator must make every effort to have 
the patient complete all withdrawal assessments at the time of withdrawal and 
complete all scheduled follow -up visits.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 16 of 103 28 Octo ber 202 1 
Confidential - Entire Page  3. Study Completion  
Patient must be taken off the study if:  
• The patient dies during the study.  
• The patient is lost to follow -up. 
• The patient withdraws consent.  
4. Patient Withdrawal from Study  
A patient may voluntarily withdraw from study treatment or withdraw consent from 
the study at any time. The investigator may also, at his or her discretion, discontinue 
a patient from participating in the  Study Treatment at any time. The Investigator 
and/or designated staff will record the date and the reason for patient withdrawal 
from the study treatment and/or study participation, as applicable . 
Statistics  This is a Phase I, open -label, dose -finding and cohort expansion study to determine 
the safety and preliminary efficacy of APR -246 in combination with venetoclax and/or 
azacitidine in patients with AML.  
The RP2D of APR -246 will be defined as the dose at which <2 out of 6 patients 
experi ence DLT during the 4 -week safety assessment period after administration of 
APR-246 in combination with venetoclax and/or azacitidine.  
Definition of Dose -Limiting Toxicity (DLT)  
An event will be considered a DLT per NCI CTCAE version 5.0 criteria if it occ urs within 
the 4 -week safety assessment period (Cycle 1 of study treatment) and is not 
attributable to the underlying disease. DLT is defined as:  
 
• Absolute neutrophil count (ANC) not recovering to >0.5 × 109/L and/or 
platelets not recovering to >25 × 109/L by day 42 of study treatment in the 
absence of active leukemia or myelodysplasia;  
• Grade ≥ 3 nausea/vomiting/diarrhea or CNS toxicity that does not resolve to 
Grade ≤ 1 within 7 days despite treatment interruption and/or maximal 
medical therapy;  
• Treatmen t-related non -hematological Grade ≥ 3 toxicity that does not 
resolve to Grade ≤ 1.  
 
A DLT will be considered related to the study treatment unless there is a clear, 
alternative explanation for the AE. A ≥ Grade 3 metabolic or electrolyte abnormalities 
that is not clinically significant and is adequately controlled within 72 hours is not to 
be considered DLT. Tumor lysis syndrome (TLS) that responds to therapy and 
resolves within 72 hours is not considered DLT.  
 
Additionally, AEs that meet the above criteria, but occur after the DLT evaluation 
period will not be defined as DLTs, but will be reported as AEs/Serious Adverse Events 
(SAEs) and will be reviewed across all cohorts during the study to help determine the 
AE profile. A patient that discontinue s therapy during Cycle 1 without DLT is 
considered evaluable for the purpose of safety only if at least 80% of scheduled Cycle 
1 dose of APR -246 in combination with venetoclax and/or azacitidine were 
administered in the first cycle.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 17 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
DRT consisting of the Medical Monitor, Site Principal Investigators, and other clinical 
research personnel that the Sponsor may deem appropriate, will hold DRM on an 
interim basis at a frequency dependent on study accrual. At these meetings, the DRT 
will review AEs and DLT and make recommendations regarding the RP2D. In the 
expansion portion of the study, the DRT will evaluate safety and tolerability after 5 
patients have completed 1 cycle of treatment in each cohort. All accumulated safety 
data will be discussed during DRMs.  
 
Determination of Sample Size  
This trial assumes a sample size of 12 – 36 patients (6 – 18 patients for each cohort) 
in the safety lead -in portion of the study and approximately 70 patients in the 
expansion portion of the study.  
Analysis Populations   
Safety population: Patients will be evaluable for safety if they receive at least one 
dose of APR -246 with venetoclax and/or azacitidine. The safety population will be 
used to summarize exposure and safety parameters.  
DLT-evaluable population: All patients who ei ther experienced a DLT during first the 
4 weeks (Cycle 1) of the study treatment or received ≥80% of scheduled Cycle 1 dose 
of APR -246 in combination with venetoclax and/or azacitidine and did not experience 
a DLT. Any individual patient who is not evaluab le for DLT will be replaced by a new 
patient through additional patient enrollment.  
Efficacy evaluable (EE) population: All patients who complete at least one treatment 
cycle of APR -246 in combination with venetoclax and/or azacitidine and who have at 
least one post -treatment clinical response assessment. Patients who fail to complete 
one treatment cycle will also be considered EE if they show clear evidence of clinically 
significant disease progression. The EE population will be the secondary analysis 
popu lation for efficacy.  
Pharmacokinetics (PK) population: Patients will be evaluable for pharmacokinetics if 
at least one post -dose sample for PK evaluation has been obtained.  
Efficacy Analyses  
CR will be summarized for all enrolled patients as the proportion  (%) of patients with 
CR. In addition to presenting the CR rate, its associated exact 95% confidence 
intervals (CI) for each treatment arm will also be presented. CR rate will not be 
formally compared between treatment arms.  
CR + CRh rate will be summarize d as the proportion of patients who achieve CR or 
CRh. CRh is  defined as bone marrow blasts <5%, ANC >0.5 × 109/L and platelets >50 
× 109/L. CR + CRi rate will be summarized as the proportion of patients who achieve 
CR or CRi.  The rate of  TI will be summarized as the proportion of patients with RBC 
and/or platelet TI for at least 56 days.  
Duration of response (DoR) is defined as the time from the date when criteria for 
response are met to the  date of relapse or progressive disease (PD) or death due to 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 18 of 103 28 Octo ber 202 1 
Confidential - Entire Page  any cause, whichever occurs first. Patients alive with no progressive disease will have 
their DOR censored at the date of the last clinical assessment. The duration of CR will 
be summarized in each treatment arm by providing duration of complete response 
(DOCR) and duration of overall response (DOR), using Kaplan -Meier methodology. 
DoR endpoints will not be formally compared between treatment arms.  
Overall response will be summarized in number (%) of patients in each category of 
responses and ORR will be analyzed by using the similar method as CR rate.  
Survival data are collected at treatment and follow -up periods. Patients will be 
followed u ntil death or withdrawal of consent for study participation. Overall survival 
(OS) is defined as the number of days from the first day of treatment to the date of 
death. Kaplan -Meier methodology will be utilized.  
Progression -free survival (PFS) is defined as the time from the first day of treatment 
to disease progression or death from AML, whichever occurs first. If neither event 
occurs, PFS will be censored at the date of the last clinical assessment. Kaplan -Meier 
methodology will be utilized.  
Safety Analy ses 
Safety data including AEs, vital signs, laboratory data, electrocardiogram (ECG), 
physical exam will be tabulated for the safety population. AEs will be tabulated by  
System Organ Class (SOC), preferred term, severity, and relationship to treatments. 
The tabulation of laboratory parameters will include the normal ranges for each 
parameter. Each value will be classified as falling above, below, or within the normal 
range. Laboratory parameters will also be tabulated by maximum NCI CTCAE v5.0 
severity grad e. 
Pharmacokinetic Analysis  
PK sampling for APR -246 are performed in Cycle 1, on Days 1, 2 and 4 , and on Day 4 
of every subsequent cycle .  
PK sampling for venetoclax is performed on Days 1, 2, 22 and 23 of Cycle 1 and on 
Day 4 of Cycles 2 – 5. 
Non -compartmental or population pharmacokinetic methods will be used to derive 
APR-246 and venetoclax PK parameters (C max, Tmax, AUC, V d and CL).  
The pharmacokinetics of APR -246 and venetoclax will be summarized using 
descriptive statistics (mean, standard  deviation, CV% mean, geometric mean, CV% 
geometric mean) and compared with historical control data.  
APR-246 AUC and C max will then be tested for association with signs of efficacy and 
safety. If an observable trend exists, a PK/PD model will be developed to evaluate the 
exposure -response relationship between APR -246 plasma exposure and outcome 
measures in the presence of venetoclax. Demographic and clinical data (ethnicity, 
current age, body weight, sex, disease status, etc.) will be utilized to assess 
interpatient variability in the PK and PK/PD relationships.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 19 of 103 28 Octo ber 202 1 
Confidential - Entire Page  LIST OF ABBREVIATIONS  
Abbreviation  Definition  
  
AE Adverse Event  
  
ALT Alanine Aminotransferase  
  
AML  Acute Myeloid Leukemia  
  
ANC  Absolute Neutrophil Count  
  
AST Aspartate Aminotransferase  
  
AUC  Area Under Curve  
  
BUN  Blood Urea Nitrogen  
  
CHF Congestive Heart Failure  
  
CI Confidence Interval  
  
Cmax Maximum Concentration  
  
CR  Complete Remission  
  
CRF Case Report Form  
 
CRh 
 Complete Remission with Partial Hematologic Recovery  
CRO  Contract Research Organization  
  
CRp  Complete Remission with Incomplete Platelet Recovery  
  
DLT Dose -Limiting Toxicity  
  
DOCR  Duration of Complete Response  
  
DOR  Duration of Overall Response  
  
DoR  Duration of Response  
  
DRM  Data Review Meeting  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 20 of 103 28 Octo ber 202 1 
Confidential - Entire Page    
DRT Data Review Team  
  
EC European Commission  
  
ECG Electrocardiogram  
  
ECOG  Eastern Cooperative Oncology Group  
  
EDTA  Ethylenediaminetetraacetic Acid 
  
EMD  Extramedullary Disease  
  
EOI End of Infusion  
  
FDA Food and Drug Administration  
  
GCP  Good Clinical Practice Guidelines  
  
HIV Human Immunodeficiency Virus  
  
HSCT  Hematopoietic Stem Cell Transplantation  
  
HMA  Hypomethylating Agent  
  
ICF Informed Consent Form  
  
ICH International Council for Harmonisation  
  
IEC Institutional Ethics Committee  
  
IHC Immunohistochemistry  
  
IMP Investigational Medicinal Product  
  
IPCW  Inverse Probability of Censoring Weights  
  
IRB Institutional Review Board  
  
IV Intravenous  
  
IWG International Working Group  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 21 of 103 28 Octo ber 202 1 
Confidential - Entire Page    
LBM  Lean Body Mass  
  
LVEF  Left Ventricular Ejection Fraction  
  
µg 
 
MDS  Microgram  
 
Myelodysplastic Syndrome  
  
MLFS  Morphologic Leukemia -Free State  
  
MTD  Maximum Tolerated Dose  
  
NCI CTCAE  National Cancer Institute – Common Terminology Criteria for 
Adverse Events  
  
NGS  Next -Generation Sequencing  
  
OS Overall Survival  
  
ORR  Overall Response Rate  
  
PFS Progression -Free Survival  
  
PK Pharmacokinetic(s)  
  
PLD Pegylated Liposomal Doxorubicin  
  
PR Partial Remission  
  
QTcF  Corrected QT Interval by Fridericia ’s formula  
  
RA Refractory Anemia  
  
RAEB  Refractory Anemia with Excess Blasts  
  
RAEB -T Refractory Anemia with Excess Blasts in Transformation  
  
RP2D  Recommended Phase II Dose  
  
SAE Serious Adverse Event  
  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 22 of 103 28 Octo ber 202 1 
Confidential - Entire Page  SAR Suspected Adverse Reaction  
  
SCT Stem Cell Transplantation  
  
SOC  System Organ Class  
  
TEAE  Treatment -Emergent Adverse Event  
  
TI Transfusion Independence  
  
tid Three Times Daily ( Ter in Die ) 
  
TLS Tumor Lysis Syndrome  
  
TrxR1  Thioredoxin Reductase 1  
  
ULN  Upper Limit of Normal  
  
USPI  US Prescribing Information  
  
VAF Variant Allele Frequency  
  
Vd Volume of Distribution  
  
WHO  World Health Organization  
  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 23 of 103 28 Octo ber 202 1 
Confidential - Entire Page  1.0 GENERAL INFORMATION  
1.1 Protocol Number and Title of the Study  
Protocol No. A19-11184   
Protocol Title: A Phase I Study to Evaluate Safety and Tolerability of APR -246 in Combination 
with Venetoclax and Azacitidine in Patients with Myeloid Malignancies  
 
1.2 Sponsor  
Aprea Therapeutics, Inc.  
 
 
 
1.3 Monitor  
  
 
 
 
 
 
1.4 Signature Authorization  
The protocol will be signed by Aprea Therapeutics , Inc. 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 24 of 103 28 Octo ber 202 1 
Confidential - Entire Page  2.0 BACKGROUND INFORMATION  
2.1 Introduction  
2.1.1  Acute Myeloid Leukemia  
AML is a group of hematopoietic neoplasms characterized by a clonal proliferation of 
myeloid precursors with a reduced capacity to differentiate into mature cells. AML is the 
most common type of acute leukemia in adults,  with an incidence of over 20,000 cases per 
year in the United States1–4.  
 
Cytogenetic and mutation testing remain critical prognostic tools to asse ss prognosis and 
plan induction and post -remission treatment strategies5. Testing peripheral blood and bone 
marrow samples using next generation sequencing (NGS) has developed into a standard of 
care for determining molecular mutations. Mutations in the tumor suppressor gene TP53  are 
found in approximately 20% of patients with  AML and are associated with an adverse 
prognosis. In addition, approximately 80% of patients with TP53 -mutant AML have a complex 
karyotype, which also confers an adverse prognosis6. 
 
Despite increased understanding of the biology and development of new therapeutic 
targets, AML treatment remains relatively unchanged, with therapies limited to intensive 
chemotherapy comprised of cytarabine and anthracycline and non -intensive therapies 
consisting of a HMA, sometimes incorporating the BCL -2 inhibitor venetoclax. Allogeneic 
stem cell transplantation is recommended for patients with high risk and relapsed or 
refractory (R/R) AML who achieve a suitable response and are eligible for  SCT.  
 
Non -intensive therapies are utilized to treat patients who are considered ineligible for 
intensive chemotherapy on the basis of advanced age, comorbidities, and low likelihood of 
achieving a response based on adverse cytogenetic/molecular features a nd/or a history of 
an antecedent hematologic disorder. Non -intensive therapies consist of the HMAs decitabine 
and azacitidine and low -dose cytarabine (LDAC)7–10. Both agents have activity in AML as initial 
induction therapy and in the relapsed setting8,9,11. Recently, HMAs12 and LDAC13 have been 
combined with venetoclax in the initial treatment of AML. In addition, HMAs have been 
combined with venetoclax to treat patients with R/R AM L14.  
 
2.1.2  TP53  Mutations in Myeloid Malignancies  
TP53  is a tumor suppressor protein that plays a pivotal role in maintaining genomic stability 
in response to DNA damage. It is mutated in over half of human cancers15,16, and such 
mutations represent an important mechanism of resistance to DNA -damaging 
chemotherapeutic agents17,18. A signific ant proportion of mutations recurrently target 
‘hot-spot’ codons. They either directly disrupt the DNA -binding domain of TP53  or cause 
conformational changes of the TP53  protein, thus leading to severely impaired TP53  function.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 25 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Mutated TP53  is predominantl y observed in therapy -related AML19,20 and/or in patients with 
complex karyotype (70 -80%)21. The reported frequency of TP53  mutations is 5 -10% in de-novo  
AML22–24. It has been demonstrated that gain of function mutations in hot spot regions can 
promote a more aggressive AML25–28. In multivariate analysis, the presence of TP53  mutations 
predicted for poor overall survival and inferior response to treatment27,29 –32. 
 
In a retrospective analysis of 55 patients who received azacitidine therapy for first line 
treatment of TP53 -mutant AML, the CR + CRi rate was 21.8%33. Though the remission rate 
was not significantly different from patients  with wild type TP53 , the median survival was 
significantly shorter (7.9 vs 12.6 months, p<.001) for patients with TP53  mutations. A similar 
median OS of 7.9 months was observed in patients with TP53 -mutant AML who received 
initial therapy with azacitidine34. Regarding patients with TP53  mutations who received 
venetoclax with HMAs, the CR/CRi rate was 47%12. In 10 patients who received venetoclax 
with LDAC, there were no CRs and 3 patients achieved CR i13. Responses in later lines are even 
poorer14. 
 
Together, these data highlight the poor outcomes of TP53 -mutant patients, even with 
recently approved venetoclax -containing therapies, and the important need for the 
development of novel therapeutic strategies, particularly in this patient population.  
 
2.2 APR -246 
 
  
 
 
 
  
 
 
2.3 Venetoclax  
Venetoclax is a BCL -2 inhibitor that approved by the U.S. FDA for use in combination with 
HMAs for the treatment of patients with newly diagnosed AML who are 75 years or older or 
who have comorbidities that preclude use of intensive induction chemotherapy.  Accelerated 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 26 of 103 28 Octo ber 202 1 
Confidential - Entire Page  approval was granted based on the results of the Phase Ib study with HMAs for patients 65 
years or older with treatment -naïve AML, ineligible for intensive chemotherapy by age or 
comorbidities35. Sixty -seven percent of patients in the study achieved CR or CR with 
incomplete count recovery (CRi). The median DoR was 11.3 months, and median overall 
survival was 17.5 months in all patients. It was shown that treatment with venetoclax in 
combination w ith an HMA leads to a decrease in oxidative phosphorylation via disruption of 
electron transport chain in a glutathione -dependent fashion and selective targeting of the 
leukemia stem cell population36.  
 
Per venetoclax US Prescribing Information (USPI)37 dated May 2020, the most common  
adverse reactions (≥ 30%) of any grade  in AML patients receiving venetoclax in combination 
with azacitidine are nausea, diarrhea, constipation, neutropenia, thrombocytopenia, 
hemorrhage, peripheral edema, vomiting, fatigue, febrile neutropenia, rash, and a nemia . 
Serious adverse reactions were reported in 75% of  AML patients receiving venetoclax in 
combination with azacitidine, with the most frequent serious adverse reactions in ≥5% of 
patients being febrile neutropenia, pneumonia (excluding fungal), sepsis (excluding fungal), 
respiratory failure, and multiple organ dysfunction syndrome.  
 
Following multiple doses under fed conditions, maximum plasma concentration of 
venetoclax are reached 5 –8 hours after dose. It is recommended that venetoclax be 
admin istered with a meal as food increases the absorption after oral administration. 
Venetoclax is cleared from systemic circulation via hepatic elimination. The terminal 
elimination half -life is approximately 26 hours. The pharmacokinetics of venetoclax do not  
change over time. Venetoclax is predominantly metabolized by CYP3A4/5. CYP3A4 inhibitors 
and inducers as well as P -gp inhibitors cause clinically relevant drug -drug interactions with 
venetoclax. For the same reason certain food must be avoided: grapefruit , grapefruit juice, 
Seville oranges (often used in marmalades), starfruit (CYP3A inhibiting), and St John’s wort 
(CYP3A inducing). Based on their metabolic profiles, a pharmacokinetic drug -drug interaction 
of venetoclax with APR -246 is considered unlikely.  
 
2.4 Azacitidine  
Azacitidine is a nucleoside metabolic inhibitor indicated by the U.S. FDA for the treatment of 
patients with the following French -American -British (FAB) MDS subtypes: refractory anemia 
(RA) or refractory anemia with ringed sideroblasts (if ac companied by neutropenia or 
thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), 
refractory anemia with excess blasts in transformation (RAEB -T), and chronic 
myelomonocytic leukemia (CMML).  
 
In 2008, azacitidine was ap proved by the European Medicines Agency (EMA) for the 
treatment of AML patients with 20 –30% bone marrow blasts, older than 64 years and who 
are ineligible for HSCT. EMA approval of azacitidine was expanded on 30 October 2015 to 
include AML patients with >3 0% bone marrow blasts.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 27 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
The recommended starting dose for the first treatment cycle, for all patients regardless of 
baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily 
for 7 days. Cycles should be repeated every 28 day s. Treatment may be continued as long as 
the patient derives clinical benefit.   
 
Azacitidine is rapidly absorbed after subcutaneous or IV administration with a V d of 76 ± 26 
L and a half -life of 41 ± 8 minutes. C max is reached after about 30 minutes. Azac itidine and its 
metabolites are known to be substantially excreted by the kidney, and the risk of adverse 
reactions to this drug may be greater in patients with impaired renal function. Urinary 
excretion is the primary route of elimination; the cumulated u rinary excretion is 85% of 
radioactive dose with less than 1% recovered in feces over 3 days.  
 
Azacitidine undergoes spontaneous hydrolysis in aqueous solution and is deaminated by 
cytidine deamidases, whereas APR -246 is glucuronidated. Drug -drug interacti on is not likely 
although both compounds and their degradation products and metabolites are primarily 
eliminated by urinary excretion. The pharmacokinetic interaction between APR -246 and 
azacitidine will be investigated in an ongoing parallel trial.  
2.5 Combi nation of Venetoclax with Azacitidine  
Venetoclax has demonstrated synergistic activity in combination with azacitidine in 
preclinical models38. This relationship was supported by clinical data from a large, 
multicenter, Phase Ib study ([STUDY_ID_REMOVED]) in elderly patients with treatment -naive AML, 
ineligible for intensive chemotherapy12. Promising efficacy and a tolerable safety profile of 
this novel combination, with a high CR + CRi rate of 73% in the 400 -mg venetoclax in 
combination wit h HMA (azacitidine or decitabine) cohort (P=0.35), low early mortality rates, 
and OS extending beyond 17 months. The median duration of CR + CRi for the venetoclax 
400 mg in combination with HMA was 12.5 months (95% CI). Patients with TP53  mutations 
achiev ed a CR/CRi rate of 47%22,39. Importantly, the best response of CR + CRi ha s been 
attained at median of 1.8 months compared with 3.5 months with azacitidine alone40. 
Response rates were similar between the azacitidine and decitabine cohorts (76% vs 71%, 
respectively). A Phase III, randomized, double -blind, placebo -controlled study of venetoclax 
400 mg combined with azacitidine i n treatment -naïve elderly and adult patients with AML 
ineligible for standard induction therapy is currently underway ([STUDY_ID_REMOVED]) and aims to 
evaluate the potential impact of venetoclax with azacitidine compared to azacitidine alone 
 
 
2.6 APR -246 Precl inical Studies  
2.6.1  Pharmacology and Mode of Action  
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 28 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
 
       
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
          
 
 
 
  
  
 
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
   
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
2.6.3  Pharmacokinetics and Metabolism in Animals  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
   
   
 
 
  
 
 
 
 
 
 
 
 
  
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 31 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
2.7 APR -246 Clinical Studies  
 
 
  
 
2.7.1  Phase I/II Study in Solid and Hematological Maligna ncies  
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
  
 
 
 
  
 
2.7.2  Phase I/II Study in TP53 -Mutant Advanced Ovarian Cancer  
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 32 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
 
 
 
 
 
2.7.3  Phase I/Ib Study in Refractory Hematologic Malignancies  
 
 
  
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 33 of 103 28 Octo ber 202 1 
Confidential - Entire Page    
 
  
  
 
 
 
2.7.5  Phase III Multicenter, Randomized, Open Label Study of APR -246 in Combination 
with Azacitidine  
 
 
   
 
 
   
 
 
 
 
 
2.7.6  APR -246 CNS Safety Overview  
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
  
 
   

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 34 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
 
 
   
 
 
         
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 35 of 103 28 Octo ber 202 1 
Confidential - Entire Page  2.8 Dose Rationale for APR -246 in Combination with Venetoclax and/or Azacitidine  
 
 
 
  
 
 
 
 
2.8.1  APR -246 and Azacitidine  
  
 
 
 
  
 
 
 
 
 
 
  
 
 
 
   
 
2.8.2  Venetoclax and Azacitidine  
The doses of venetoclax and azacitidine for patients receiving doublet therapy (APR -246 and 
venetoclax) or triplet therapy (APR -246, venetoclax and azacitidine) are consistent with the 
doses recommended in the venetoclax USPI48 for patients with AML.  
 
2.8.3  Venetoclax and APR -246 
 
 
 
  
 
  

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 36 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
 
 
 
       
 
 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.8.4  Expansion Cohorts in Front Line AML  
 
  
 
   
 
  
 
 
 
 
  
 
 
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
   
  
  
 
   
 
 
 
 
 
 
  
  
 
   
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
  

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 38 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9.2  Potential Benefits  
Patients with TP53 -mutant myeloid malignancies, including AML, have a poor prognosis and 
unmet med ical need. Azacitidine and venetoclax represent standard of care agents for 
TP53 -mutant AML. APR -246 in combination with azacitidine has demonstrated compelling 
clinical efficacy and a manageable safety profile in patients with TP53 -mutant MDS/AML, and 
APR-246 has demonstrated in vitro  synergy with azacitidine and venetoclax. The purpose of 
this clinical trial is to define the safety and tolerability of APR -246 in combination with 
venetoclax and/or azacitidine in patients with TP53 -mutant AML and to determi ne 
preliminary efficacy. Given that TP53 -mutant MDS and AML patients have a limited life 
expectancy and lack of effective treatments, the benefit/risk assessment supports the use of 
APR-246 in this trial.  
 
2.10 Characteristics of a Well -Conducted Trial  
The following characteristics of an adequate and well -conducted trial will be implemented:  
 
1. The Investigators will be well qualified by scientific training and experience.  
2. Detailed CRFs will be completed for every patient.  
3. Requirements for institutional ethic s review as set forth by the appropriate 
Institutional Review Board/Independent Ethics Committee (IRB/IEC), Title 21 Code of 
Federal Regulations (CFR) Part 56, the European Union Directive 2001/20/EC and its 
associated Detailed Guidances, European Union GC P Directive 2005/28/EC, the ICH 
Guideline for GCP, Sections 3 and 4, and the terms of the Declaration of Helsinki 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 39 of 103 28 Octo ber 202 1 
Confidential - Entire Page  (2013), will be followed.  
4. Requirements for informed consent in accordance with institutional guidelines, FDA 
requirements as specified in Tit le 21 CFR, Part 50, the European Union Directive 
2001/20/EC and its associated Detailed Guidances, European Union GCP Directive 
2005/28/EC, the ICH Guideline for GCP, Section 4.8, and the terms of the Declaration 
of Helsinki (2013), will be followed.  
5. Safe ty data will be recorded and evaluated.  
6. Routine monitoring visits will be conducted by the Sponsor’s representative to ensure 
data accuracy.  
7. Drug accountability will be strictly maintained.  
8. This trial will be conducted according to GCP, the protocol and  applicable regulatory 
requirements.  
 
2.11 Patient Population  
This study will enroll adult male and female patients of age ≥ 18 years with documented 
diagnosis of AML, according to WHO classification, and documented TP53  mutation, which is 
not benign or likely benign, who also meet the eligibility requirements of this protocol.  
 
 
3.0 TRIAL OBJECTIVES AND PURPOSE  
Primary objective:  
To evaluate the safety and tolerability of administration of APR -246 in combination with 
venetoclax and/or azacitidine in patients with TP53 -mutant myeloid malignancies.  
 
Secondary objectives:  
1. To assess the clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with myeloid malignancies by determination of CR rate.  
2. To assess the clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with myeloid malignancies by determination of CR plus CRi 
rate.  
3. To assess the clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with myeloid malignancies by determination of CR plus CRh 
rate.  
4. To assess the clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with myeloid malignancies by determination of ORR.  
5. To assess the clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with AML by determination of PFS. 
6. To assess the clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with AML by determination of transition rate to HSCT.  
7. To assess the clinical activity of APR -246 in combination with venetocla x and/or 
azacitidine in patients with AML by determination of OS. 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 40 of 103 28 Octo ber 202 1 
Confidential - Entire Page  8. To assess clinical activity of APR -246 in combination with venetoclax and/or 
azacitidine in patients with AML by determining the rate of RBC and/or platelet TI for 
at least 56 days.  
9. To deter mine the pharmacokinetic profile of APR -246 and venetoclax.  
 
Exploratory objectives:  
1. To investigate molecular biomarkers for response prediction and disease monitoring 
in baseline and serial bone marrow or blood samples.  
 
 
4.0 TRIAL DESIGN  
4.1 Overview of Trial Design  
Study treatment may be administered on an outpatient basis. No investigational or 
commercial agents or therapies other than those described below may be administered with 
the intent to treat the patient's disease. Hydroxyurea may be used for control of leukocytosis.  
The study includes a safety lead -in dose -finding portion followed by expansion portion. 
During the safety lead -in portion of the study, two cohorts will independently enroll patients 
following a 3 + 3 design.  
Safety lead -in co hort 1 will enroll patients with AML or MDS who have received at least one 
prior HMA regimen for MDS. These patients will receive APR -246 at 4.5 g/day on days 1 – 4 
of each 28 -day cycle administered concurrently with venetoclax that is given orally at the 
dose of 400 mg daily once the ramp -up phase is completed. If a prophylactic antifungal agent 
is administered concurrently, the daily dose of venetoclax should be determined based on 
institutional practice and current prescribing information for venetoclax.  Safety lead -in 
cohort 2 will enroll patients with previously untreated TP53 -mutant AML (prior MDS is 
allowed, but not treatment with HMA), who will receive APR -246 at 4.5 g/day on days 1 – 4 
administered concurrently with venetoclax given orally at the do se of 400 mg daily and with 
azacitidine at the standard dose of 75 mg/m2 over 7 consecutive days as a subcutaneous 
injection or IV infusion on days 1 – 7 of each 28 -day cycle.  
Each cohort will enroll up to 6 patients. DLT will be assessed after three pati ents have been 
enrolled in respective cohort and the last enrolled patient has completed the 4 -week safety 
assessment period (i.e., one cycle of combination regimen). A patient that discontinues 
therapy during Cycle 1 without DLT is considered evaluable fo r the purpose of safety only if 
at least 80% of scheduled doses of APR -246 in combination with venetoclax and/or 
azacitidine were administered in the first cycle. At the first dose level of 4.5 g/day of APR -246, 
if ≤1 patient out of 3 experiences a DLT, 3 additional patients will be enrolled. If ≤1 patient 
out of 6 experiences DLT, the dose level (4.5 g/day of APR -246) will be deemed the RP2D for 
that cohort. If ≥2 patients out of the total 3 –6 patients in the cohort experience DLT, the study 
will continue enrollment at Dose Level -1 (4.0 g/day of APR -246). If ≤1 patient out of 6 
experiences DLT at this dose level, the dose level (4.0 g/day of APR -246) will be deemed the 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 41 of 103 28 Octo ber 202 1 
Confidential - Entire Page  RP2D for that cohort. If ≥2 patients out of the total 3 – 6 patients at that dose level experience 
DLT, the study will continue enrollment at Dose Level -2 (3.5 g/day of APR -246). If ≤1 patient 
out of 6 experiences DLT at this dose level, the dose level (3.5 g/day of APR -246) will be 
deemed the RP2D for that cohort. If ≥2 patients out of the total 3 –6 patients at this dose level 
experience DLT, no additional patients will be enrolled at this dose. The trial will be halted, 
and the DRT will consider potential future dosing modifications.  
 
Table 2. APR -246 Dose Levels  
 
Dose Modific ation  APR -246 Dose  
Starting Dose Level 
(DL) APR-246 4.5 g/day  
1.5 g (for first 45 minutes) + 3.0 g (for 5 hours 15 minutes)  
Dose Level 
Reduction  
-1 (DL -1) APR-246 4.0 g/day  
1.33 g (for first 45 minutes) + 2.67 g (for 5 hours 15 minutes)  
Dose Level 
Reduction  
-2 (DL -2) APR-246 3.5 g/day  
1.17 g (for first 45 minutes) + 2.33 g (for 5 hours 15 minutes)  
 
The expansion portion will begin once the RP2D of APR -246 in combination with venetoclax 
and/or azacitidine have been determined in order to assess the antitumor activity of these 
combinations. Approximately 70 patients will be enrolled in up to five cohor ts, as outlined in 
Table 3:  
Table 3. Study Treatment and Prior Therapy by Cohort  
Cohort  Disease  Study 
Treatment  Prior Therapy Permitted  
   VEN  HMA  LDAC  APR -
246 SCT IC 
Safety Lead -In Cohorts  
Cohort 1  F/L AML  APR-246 + 
VEN no ≥ 1 prior 
for MDS 
required  no no yes for 
MDS  no 
Cohort 2  F/L AML  APR-246 + 
VEN + AZA  no no no no no no 
Expansion Cohorts  
Cohort 1  F/L AML  APR-246 + 
VEN no yes for 
MDS  no no yes for 
MDS  no 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 42 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Cohort 2  F/L AML  APR-246 + 
VEN + AZA  no no no no no no 
Cohort 3  R/R 
AML  APR-246 + 
VEN yes yes Ye s yes for 
MDS  yes yes 
Cohort 4  R/R 
AML  APR-246 + 
VEN + AZA  yes no no yes for 
MDS  yes ≤ 1 prior  
Cohort 5  F/L AML  APR-246 + 
AZA no no no no no no 
Abbreviations: AZA = azacitidine; F/L = front line; HMA = hypomethylating agent; IC = intensive 
chemotherapy; LDAC = low -dose cytarabine; MDS = myelodysplastic syndrome; R/R = refractory or 
relapsed; SCT = stem cell transplant; VEN = venetoclax  
Cytopenia and related adverse events (thrombocytopenia, anemia,  neutropenia, and febrile 
neutropenia) are common in patients with AML, particularly in patients with  baseline 
neutropenia or those with secondary AML.  
 
For patients receiving venetoclax in co mbination with azacitidine, in a case of CRi or a 
morphologic leukemia -free bone marrow (MLFS) after  completion of Cycle 1, administration 
of venetoclax and APR -246 may be interrupted to allow for ANC recovery  from Day 29 until 
ANC ≥0.5 × 109/L. Blood counts can be assessed within 4 weeks of bone marrow biopsy for 
response assessments. Cycle 2 administration of azacitidine  will also be delayed until ANC 
≥0.5 × 109/L. Both venetoclax, azacitidine, and APR -246 will  resume on the same day after 
the interru ption. If a patient presents with new onset  Grade 4 neutropenia for more than 1 
week during subsequent cycles, unless it is thought  to be due to the underlying disease, 
venetoclax dosing may be interrupted until  ANC is ≥0.5 × 109/L. For subjects in CR/CRi who 
required interruption or  delay of study drug administration for cytopenia (neutropenia or 
thrombocytopenia)  venetoclax may be administered for 14 -21 days out of 28 days during 
each of the  subsequent cycles.  
 
If hematologic recovery is achieved within 1 4 days after completion of  the cycle, the duration 
of venetoclax is reduced to 21 days of the cycle. If a 25% increase has not been  achieved 
within 14 days after the completion of a cycle, azacitidine dose adjustment can be made 
based on bone marrow cellul arity. In the setting of bone marrow hypocellularity, the dose of 
azacitidine in the next treatment cycle should be reduced to 50% for 15 -50% hypocellularity 
and to 33% for <15% hypocellularity.  
 
In each portion of the study, patients may continue treatmen t as long as toxicity remains 
acceptable and the patient has not withdrawn consent. Response and progressive disease 
will be assessed based on the IWG AML response criteria ( APPENDIX I ) after every treatment 
cycle the first year, then every two cycles thereafter.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 43 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
4.2 End of Study  
The end of the study is defined as the date of the last visit of the last patient undergoing the 
trial.  
 
4.3 Drug Products  
4.3.1  APR -246 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 Administration : Venetoclax should be taken orally, with food, at a dose  of 400 mg 
daily once the ramp -up phase is completed. If no p rophylactic antifungal agent is  
administered concurrently, the ramp -up phase should consist of 100, 200, and 400 mg of 
venetoclax once daily given on days 1, 2, and 3 of Cycle 1, respectively. Fo r day 4 of Cycle 1 
and beyond, the venetoclax dose is 400 mg once daily given in combination with APR -246 
with and without azacitidine. If a p rophylactic antifungal agent is  administered concurrently, 
the ramp -up phase and maintenance dose of venetoclax sh ould be determined based on 
institutional practice and current prescribing information for venetoclax  (see APPENDIX VIII ). 
The dose of venetoclax should be modified accordingly to account for changes in a patient’s 
antif ungal medication use.  

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 44 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
4.3.3  Azacitidine  
Chemical Name:  4-amino -1--D-ribofuranosyl -s-triazin -2(1H) -one 
 
Formulation, preparation, storage and stability:  Please see commercial package insert 
approved by regulatory agencies56. 
 
Route of Administration:  Subcutaneous injection, or IV infusion for 7 consecutive days (Days 
1-7). Subcutaneous route is preferred but IV administration is acceptable at the Investigator’s 
discretion. The same route should be maintained over the 7 -day treatment period.  
 
4.4 Duration of Therapy  
Patients may remain on study treatment to the end of the trial while deriving clinical benefit, 
unless unacceptable toxicity, progression, death or patient withdrawal requires 
discontinuation . For patients without disease progression or unacceptable toxicity, study 
treatment should proceed for a minimum of 6 months to allow time for clinical response. 
Patients may remain on protocol therapy after relapse or progression if they are continuing 
to derive clinical benefit in the opinion of the Investigator.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 45 of 103 28 Octo ber 202 1 
Confidential - Entire Page  4.5 Trial Discontinuation  
For reasonable cause, either the Investigator or the Sponsor may terminate this study 
prematurely. Written notification of the termination is required. Conditions that ma y warrant 
termination include, but are not limited to:  
 
• The discovery of an unexpected, significant, or unacceptable risk to the patients enrolled 
in the study.  
• Failure of the Investigator to enter patients at an acceptable rate.  
• Insufficient adherence to protocol requirements (non -compliance).  
• Lack of evaluable and/or complete data.  
• Decision to modify the developmental plan of the drug.  
• A decision on the part of the Sponsor to suspend or discontinue development of the drug.  
 
4.6 Drug Accountability/Disposition  of Clinical Trial Supplies  
Drug accountability records will be maintained for all clinical trial supplies.  
 
All unused clinical trial supplies will be destroyed per the institution’s standard operating 
procedure. Destruction of drug and trial supplies mus t be documented, and the 
documentation will be reviewed by/sent to the Sponsor or their Designee.  
 
4.7 Registration  
Prior to registration and any study -specific evaluations being performed, all patients must 
have given written informed consent for the study and must have completed the pre -study 
evaluations (see Section 7.1). Patients must meet all of the eligibility requirements listed in 
Section 5.0. Patients will be registered on the study by using the  
Interactive Web Response System (IWRS) automated patient registration system.  
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 46 of 103 28 Octo ber 202 1 
Confidential - Entire Page  5.0 SELECTION AND WITHDRAWAL OF PA TIENTS  
5.1 Inclusion Criteria for Patients in Safety Lead -In Cohorts  
1. Signed ICF and ability to comply with protocol requirements.  
2. Documented diagnosis of initial or relapsed AML according to World Health Organization 
(WHO) classification.  
3. Adequate organ funct ion as defined by the following laboratory values:  
a. Creatinine clearance >30 mL/min (by Cockcroft -Gault method; APPENDIX II ), 
b. Total serum bilirubin <1.5 × ULN unless due to Gilbert’s syndrome, leukemic organ 
involvement, hemolysis or considered an effect of regular blood transfusions,  
c. ALT and AST <3 × ULN, unless due to leukemic organ involvement.  
4. Age ≥18 years at the time of signing the ICF.  
5. At least one TP53  mutation which is not benign or likely benign.  
6. ECO G performance status of 0, 1 or 2 ( APPENDIX III ). 
7. Projected life expectancy of ≥12 weeks.  
8. Negative serum or urine pregnancy test prior to study treatment initiation in female 
patients of childbearing potential.  
9. Females o f childbearing potential and males with female partners of childbearing 
potential must be willing to use an effective form of contraception such as latex condom, 
hormonal birth control, intrauterine device or double barrier method ( APPENDIX IV ) 
during chemotherapy treatment and for at least six months thereafter.  
 
5.2 Exclusion Criteria for Patients in Safety Lead -In Cohorts  
1. Prior treatment for TP53 -mutant AML not permitted per Table 3. 
2. Known history of HIV or active hepatitis B or active hepatitis C infection.  
3. Any of the following cardiac abnormalities:  
a. Myocardial infarction within six months prior to registration,  
b. New York Heart Association Class III or IV ( APPENDIX V ) heart failure or known LVEF 
<40%;  
c. A history of familial long QT syndrome,  
d. Symptomatic atrial or ventricular arrhythmias not controlled by medications,  
e. QTcF ≥470 msec, unless due to underlying bundle branch block and/or pacemaker 
and with approval of the Medical Monitor.  
4. Concomitant malignancies for which patients are receiving active therapy at the time of 
signing consent. For example, patients with adequat ely treated basal or  squamous cell 
carcinoma of the skin, adequately treated carcinoma in situ  (e.g. cervix), or breast cancer 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 47 of 103 28 Octo ber 202 1 
Confidential - Entire Page  receiving adjuvant endocrine therapy may enroll irrespective of the time of diagnosis 
with Medical Monitor approval.  
5. Known active  CNS involvement from AML. A diagnostic lumbar puncture is not required 
in the absence of suspicion for CNS disease.  
6. Malabsorption syndrome or other condition that precludes enteral route of 
administration.  
7. Pregnancy or lactation.  
8. Active uncontrolled syste mic infection (viral, bacterial or fungal).  
 
5.3 Inclusion Criteria for Patients in Expansion Cohorts  
1. Signed ICF and ability to comply with protocol requirements.  
2. Newly diagnosed or R/R AML according to WHO classification  with permitted prior 
therapy, as per Table 3. For patients with newly diagnosed AML bone marrow and /or 
blood evidence of AML with ≥20% blasts is required . For patients with newly diagnosed 
AML, prior therapy with HMA and/or any chemotherapeutic agent for MDS is excluded.  
3. Adequate organ function as defined by the following laboratory values:  
a. Creatinine clearance >30 mL/min (by Cockcroft -Gault method; APPENDIX II ), 
b. Total serum bilirubin <1.5 × ULN unless due to Gilbert’s syndrome, leukemic organ 
involvement, hemolysis or considered an effect of regular blood transfusions,  
c. ALT and AST <3 × ULN, unless due to leukemic organ in volvement.  
4. Age ≥18 years at the time of signing the ICF.  
5. At least one TP53  mutation which is not benign or likely benign , based on central TP53  
testing results.  If local TP53  mutation and/or p53 IHC results become available  before 
central TP53  mutation results, enrollment may be made based on local results with 
Medical Monitor approval .  
6. ECOG performance status of 0, 1 or 2 ( APPENDIX III ). 
7. Projected life expectancy of ≥12 weeks.  
8. Negative serum or urine pregnancy test prior to study treatment initiation in female 
patients of childbearing potential.  
9. Females of childbearing potential and males with female partners of childbearing 
potential must be willing to use an effective form of contraception such as la tex condom, 
hormonal birth control, intrauterine device or double barrier method ( APPENDIX IV ) 
during chemotherapy treatment and for at least six months thereafter.  
 
5.4 Exclusion Criteria for Patients in Expansion Cohorts  
1. Known history of MPN (i.e., polycythemia vera, essential thrombocythemia and primary 
myelofibrosis are excluded).  
2. Known history of HIV or active hepatitis B or active hepatitis C infection.  
3. Any of the following cardiac abnormalities:  
a. Myocardial infarction wi thin six months prior to registration,  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 48 of 103 28 Octo ber 202 1 
Confidential - Entire Page  b. New York Heart Association Class III or IV ( APPENDIX V ) heart failure or known LVEF 
<40%,  
c. A history of familial long QT syndrome,  
d. Symptomatic atrial or ventricular arrhythmias not contr olled by medications,  
e. QTc ≥470 msec calculated from a mean of 3 ECG readings using Fridericia’s correction 
(QTcF = QT/RR0.33).  
4. Concomitant malignancies for which patients are receiving active therapy at the time of 
signing consent. For example, patients w ith adequately resected basal or squamous cell 
carcinoma of the skin, adequately resected carcinoma in situ  (e.g. cervix), or breast cancer 
receiving adjuvant endocrine therapy may enroll irrespective of the time of diagnosis 
with Medical Monitor approval.  
5. Prior exposure to anticancer therapies including chemotherapy, radiotherapy or other 
investigational therapy, including targeted small molecule agents within 14 days of the 
first day of study drug treatment or within 5 half -lives prior to first dose of st udy drug.  
6. Prior exposure to biologic agents (e.g. monoclonal antibodies) for anti -neoplastic intent 
within 14 days prior to first dose of study drug.  
7. Known active CNS involvement from AML. A diagnostic lumbar puncture is not required 
in the absence of susp icion for CNS disease.  
8. Malabsorption syndrome or other condition that precludes enteral route of 
administration.  
9. Pregnancy or lactation.  
10. Active uncontrolled systemic infection (viral, bacterial or fungal).  
 
5.5 Inclusion of Women, Minorities and Children  
Both men and women and members of all races and ethnic groups are eligible for this study. 
Children are not eligible for this study because the safety and tolerability of the proposed 
dosing schedule has not been determined in adults.  
 
5.6 Withdrawal Criteria  
Protocol therapy can continue for patients receiving clinical benefit, unless one or more 
study treatment discontinuation criteria are met, or at the patient’s discretion, or if the study 
is terminated.  
 
5.6.1  Study Treatment Discontinuation  
Study trea tment must be discontinued if:  
• Evidence of disease progression. Patients who have relapsed or progressive disease 
but who are continuing to derive clinical benefit in the opinion of the investigator may 
continue to receive study treatment.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 49 of 103 28 Octo ber 202 1 
Confidential - Entire Page  • A patient become s pregnant.  
• A patient is significantly non -compliant with the requirements of the protocol.  
• A patient has an adverse experience that would, in the Investigator’s judgment, make 
continued participation in the study an unacceptable risk.  
• The patient starts new treatment for their underlying disease.  
 
5.6.2  Study Completion  
Patient must be taken off the study if:  
• The patient dies during the study.  
• The patient is lost to follow -up. 
• The patient withdraws consent.  
 
5.6.3  Withdrawn Patients  
When a patient is removed from the study treatment, the Investigator will clearly document 
the reason in the medical record and complete the appropriate CRF page describing the 
reason for discontinuation. In addition, every effort should be made to complet e the 
appropriate assessments listed in Section 7.3. 
 
5.7 Noncompliance  
All instances of protocol deviations will be recorded according to guidelines per Sponsor’s 
Representative.  
 
6.0 TREATMENT OF PATIENTS  
6.1 Drug Preparation and Administration  
Study treatment may be administered on an outpatient basis. No investigational or 
comme rcial agents or therapies other than those described below may be administered with 
the intent to treat the patient's disease.  
 
6.1.1  APR -246 
APR-246 is administered as a 6 -hour IV infusion daily on Days 1 –4 of each 28 -day cycle. 
APR-246 fixed dose is 4.5 g. AP R-246 is administered in a 2 -step infusion:  
 
Step 1 : Loading dose of 1.5 g for the first 45 minutes (± 2 min)  
Step 2 : Maintenance dose of 3 g over 5 hours 15 minutes (± 30 min)  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 50 of 103 28 Octo ber 202 1 
Confidential - Entire Page  In each portion of the study, if patients develop intolerable toxicity(ies) to  APR-246 in 
combination with venetoclax and azacitidine, the dose of APR -246 may be reduced (please 
consult Section 4.1 and Table 2). 
APR-246 vials are to be stored at 2 -8C (35.6 -46.4F). At the pharmacies and at the study 
centers, the prepared APR -246 study product (diluted in sodium chloride so lution) is to be 
stored at not more than 25 C. The infusion should be completed within 24 hours from the 
time of preparation.  
 
Detailed instructions on vial concentration, preparation and dispensing can be found in the 
Pharmacy Binder. The infusion timing , including start/stop times and the time of rate change, 
must be recorded.  
 
6.1.2  Venetoclax  
After ramp -up (see below), venetoclax tablets at the dose 400 mg (4 tablets) should be taken 
orally once daily with a meal and water , at approximately the same time every day. On days 
1–4 of Cycle 1 it is recommended that venetoclax is taken approximately one hour after start 
of APR -246 infusion. On these days’ patients will consume a low -fat meal prior to venetoclax 
consumption. Start ing at cycle 2 venetoclax can be taken before or after start of APR -246 
infusion (± 2 hours).  
 
During Cycle 1, treatment with venetoclax should start with a ramp -up phase. If no 
prophylactic antifungal agent is  administered concurrently, the ramp -up phase should 
consist of 100, 200, and 400 mg of venetoclax once daily given on days 1, 2, and 3 of Cycle 1, 
respectively. For day 4 of Cycle 1 and beyond, the venetoclax dose is 400 mg once daily given 
in combination with APR -246 with and without azacitidine. If  a prophylactic antifungal agent 
is administered concurrently, the ramp -up and maintenance dose of venetoclax should be 
determined based on institutional practice and current prescribing information for 
venetoclax (please see APPENDIX VIII ). 
 
If required, any dosage modifications of venetoclax should be done based on clinical 
judgement and institutional practice.  
 
Detailed instructions on preparation and administration can be found in the Pharmacy 
Binder and current packa ge insert.  
 
6.1.3  Azacitidine  
Azacitidine is given at the standard dose of 75 mg/m2 subcutaneously or intravenously over 
7 consecutive days, Days 1 –7. On Days 1 –4 azacitidine is administered immediately after the 
APR-246 infusion. SC method is preferred but IV i s allowed at the Investigator’s discretion. 
The same route should be maintained over the 7 -day treatment period (whichever route is 
used on Day 1, the other days should follow the same route of administration). Detailed 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 51 of 103 28 Octo ber 202 1 
Confidential - Entire Page  instructions on preparation and admi nistration can be found in the Pharmacy Binder, 
current package insert, and in Section 6.2, below. The administration of azacitidine may be 
interrupted by up to 3 days to account for institutional administration practices and policies 
in addition to holidays.  
 
6.1.3.1  Administration on the Days of PK Blood Sampling  
On Cycle 1 Day 1, in subjects receiving APR -246 in combination with venetoclax and 
azacitidine, APR -246 is the first agent to be administered after the baseline blood sample for 
PK analysis is collected. Fifteen (15) minutes after  the start of the infusion, the subject is 
asked to have breakfast. One (1) hour after the start of APR -246, the subject is to take 
venetoclax. Azacitidine is to be administered after the infusion of APR -246.  
 
After C1, venetoclax can be taken before or af ter start of APR -246 (2 hrs) and after the 
baseline PK sample is obtained, as indicated in the Schedule of Study Evaluations . 
 
On Day 1 of Cycle 1 patients will come to the clinic for PK blood sampling without taking the 
venetoclax in the morning. Patients will receive a low -fat meal and take the venetoclax within 
30 min after the meal is finished and a baseline blood sample is taken.  
 
6.1.4  Dose -Limiting Toxicity  
An event will be considered a DLT per NCI CTCAE version 5.0 c riteria if it occurs within 4 -week 
safety assessment period (Cycle 1 of study treatment) and meets at least one of the criteria 
below:  
 
• Absolute neutrophil count (ANC) not recovering to >0.5 × 109/L and/or platelets not 
recovering to >25 × 109/L by day 42 of study treatment in the absence of active 
leukemia/myelodysplasia;  
• Grade ≥ 3 nausea/vomiting/diarrhea or CNS toxicity that does not resolve to Grade ≤ 
1 within 7 days despite treatment interruption and maximum medical therapy;  
• Treatment -related non -hemat ological Grade ≥ 3 toxicity that does not resolve to 
Grade ≤ 1.  
 
A DLT will be considered related to the study treatment unless there is a clear, alternative 
explanation for the AE. A ≥ Grade 3 metabolic or electrolyte abnormalities that is not clinically 
significant and is adequately controlled within 72 hours is not to be considered DLT. A tumor 
lysis syndrome that responds to therapy and resolves within 72 hours is not to be considered 
DLT.  
 
Additionally, AEs that meet the above criteria, but occur after the DLT evaluation period will 
not be defined as DLTs, but will be reported as AEs/Serious Adverse Events (SAEs) and will 
be reviewed across all cohorts during the study to help determine the AE profile. A patient 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 52 of 103 28 Octo ber 202 1 
Confidential - Entire Page  that discontinues therapy duri ng Cycle 1 without DLT is considered evaluable for the purpose 
of safety only if at least 80% of doses of APR -246 in combination with venetoclax with and 
without azacitidine were administered in the first cycle.  
 
Patients who are tolerating APR -246 in comb ination with venetoclax and/or azacitidine, will 
not have to discontinue dosing prematurely due to the occurrence of DLTs in another patient 
in the same cohort, unless decided by the DRT. If requested by the Investigator, depending 
on the nature of the DLT  and patient status, the DRT and the Sponsor may allow a patient to 
continue with study treatment at a reduced dose.  
 
6.1.5  Recommended Phase II Dose (RP2D)  
The RP2D of APR -246 will be defined as the dose at which <2 out of 6 patients experience 
DLT during the 4-week safety assessment period after administration of APR -246 in 
combination with venetoclax and/or azacitidine.  
 
DRT consisting of the Medical Monitor, Site Principal Investigators, and other clinical research 
personnel that the Sponsor may deem appropr iate, will hold DRM on an interim basis at a 
frequency dependent on study accrual. At these meetings, the DRT will review AEs and DLTs 
and make recommendations regarding the RP2D. In the expansion portion of the study, the 
DRT will evaluate safety and tole rability after 5 patients have completed 1 cycle of treatment 
in each cohort. All accumulated safety data will be discussed during DRMs.  
 
6.2 Dose Interruptions/Withholding  
Study treatment may be withheld from a patient based on the Investigator‘s decision in the 
event of intercurrent illness, AE, administrative reasons, or other reasons. If the patient‘s 
condition subsequently improves, or the situation that resulted in withholding study drug 
rectifies itself, the Investigator may re sume dosing as soon as possible, unless the delay is 
more than 4 weeks.  
 
Dosing should be delayed for any DLT -equivalent toxicity and possible NCI CTCAE > Grade 2 
AEs considered related to study medication. At the Investigator’s discretion, dosing may 
reco mmence when the toxicity has resolved to Grade 2 or less. Immune -related reactions or 
allergy should resolve to ≤ Grade 1.  
 
Treatment will be discontinued if a TEAE has not resolved (to acceptable grade) after ≤4 
weeks.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 53 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6.3 Supportive Management  
6.3.1  APR -246 
This section outlines the requirements for proceeding with treatment with APR -246, and the 
protocol rules for APR -246 dose modification due to toxicity.  
 
At screening, 12 -lead ECGs should be collected in triplicate to confirm QT interval does not 
exceed 470 ms ec in patients without pre -existing bundle branch block (BBB) and/or 
pacemaker.  For patients with pre -existing BBB and/or pacemaker, QTcF at screening should 
not exceed baseline reading known per medical history . QT interval must be calculated from 
a mean  of all three ECG readings using Fridericia’s correction (QTcF = QT/RR0.33). 
 
During Cycle 1 ECG should be collected in triplicate prior to infusion of APR -246 and at the 
end of infusion (EOI) of APR -246 (6 hours after start of infusion, ±30 min) on Days 1 –4. QTcF 
must be calculated from a mean of all three ECG readings to confirm it does not exceed 470 
msec in patients without pre -existing BBB and/or pacemaker. For patients with pre -existing 
BBB and/or pacemaker, QTcF measurements in Cycle 1 should be at o r below values 
recorded during screening period .  
 
If a pre -dose ECG shows QTcF ≥470 msec, the QTc reading should be confirmed by manual 
assessment using Fridericia’s correction (QTcF = QT/RR0.33). Serum concentrations of 
electrolytes should be monitored a nd corrected, if necessary. Additionally, concomitant 
medication should be reviewed and adjusted, if necessary. ECG may be repeated at any time, 
including the same day. APR -246 may only be administered when QTcF has returned to <470 
msec. If APR -246 is giv en on the same day, procedures outlined in the Schedule of Study 
Evaluations ( Table 8) must be followed. If APR -246 cannot be administered on the same day, 
that dose must be omitted from the cycle.  
 
If there is a significant change in QTcF, defined as either: a) increase >60 msec from baseline 
(or pre -dose), or b) increase to an absolute value ≥501 msec, i.e. consistent with NCI CTCAE 
Grade 3 QTc prolongation, QTc prolongation must be confirmed by a manual assessment of 
the ECG, and using Fridericia’s correction (QTcF = QT/RR0.33). If confirmed, the APR -246 
therapy should be interrupted until a cause (electrolyte disorders or an effect of a 
concomi tant medication) has been identified and addressed, and QTcF has returned to <470 
msec. If all other causes for clinically significant QT interval prolongation are excluded, APR -
246 must be permanently discontinued.  
 
During subsequent cycles ECG should be collected in triplicate prior to infusion of APR -246 
on Day 1 of each cycle. QTcF must be calculated from a mean of all three ECG readings to 
confirm it does not exceed 449 msec  in patients without pre -existing BBB and/or pacemaker. 
For patients with pre -existing BBB and/or pacemaker, QTcF measurements in subsequent 
cycles should be at or below values recorded during the screening period.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 54 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
If pre -dose QTcF is 450 -469 msec  in patients with and without pre -existing BBB and/or 
pacemaker, APR -246 may be admini stered, and additional triplicate ECG should be 
performed at the EOI (6 hours after start of infusion, ±30 min).  
 
If post -dose ECG shows a significant change in QTcF, defined as either: a) increase >60 msec 
from baseline (or pre -dose), or b) increase to a n absolute value ≥501 msec, i.e. consistent 
with NCI CTCAE Grade 3 QTc prolongation, QTc prolongation must be confirmed by a manual 
assessment of the ECG, and using Fridericia’s correction (QTcF = QT/RR0.33). If confirmed, the 
therapy should be interrupted  until a cause (electrolyte disorders or an effect of a 
concomitant medication) has been identified and addressed, and QTcF has returned to <470 
msec. If all other causes for clinically significant QT interval prolongation are excluded, APR -
246 must be per manently discontinued. If QTcF is unchanged or there is no significant 
change, additional ECG is not required during that cycle.  
 
If repeated QTcF measurements show a stable QTcF <450 msec, or if QTcF remains stable 
within the interval of 450 –469 msec with  no significant change at the EOI during several 
cycles of treatment, reducing the number of ECGs performed in the study may be discussed 
with the Medical Monitor.  
 
If a patient starts treatment with another medication known to prolong QT interval at any 
time during the study therapy, an additional pre - and post -dose (6 hours after start of 
infusion, ±30 min) ECG should be performed on the next treatment day.  
 
6.3.2  Management of CNS Adverse Events  
If a patient reports any clinical AE of any grade during the ad ministration period of APR -246 
that could be considered to originate from the CNS (e.g. dizziness, vertigo, nausea) then the 
patient will be given a rescue medication as per the institutional standard of care.  
 
Dose modifications of APR -246 have been succe ssfully used to manage potential CNS effects 
occurring during the infusion ( Table 4). For any clinical AE Grade ≥ 3, the infusion of APR -246 
should immediately be stopped, and if all symptoms resolve to CTCAE ≤  Grade 1 within 2 
hours, the infusion of APR -246 may be resumed at the same infusion rate. If the same 
symptoms do occur or increase in severity during re -challenge the infusion of APR -246 
should be stopped.  
 
If the event lasts longer than 2 hours, then the APR -246 infusion should be discontinued for 
that day, the remaining drug should be discarded.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 55 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Table 4. Management of CNS Adverse Events (Dizziness, Dyskinesia a nd Ataxia)  
Worst toxicity  Dose Modifications for APR -246 
Grade 1  Maintain dose level  
Grade 2  If resolved to ≤ Grade 1 with medical therapy, continue same dose level  
If not resolved despite treatment interruption and maximal medical therapy, 
stop infusion and  1 dose level for subsequent dose  
Grade ≥ 3  Stop infusion and give medical therapy. If resolved (to ≤  Grade 1) with medical 
therapy, infusion may continue at the Investigator’s discretion.  
  1 dose level for subsequent dose  
Grade 4  Permanently discontinue patient from APR -246.  
 
In prior studies, prochlorperazine 10 mg orally tid (three times daily) has been reported to 
be an effective treatment that may also be used prophylactically. When prochlorperazine is 
used prophylactically, start the day prior to the Day 1 and continue 10 mg tid to day 4 (as 
needed). The US label for prochlorperazine does not list QT interval prolongation as a known 
risk associated with use of this drug.  
 
6.3.3  Management of Nausea and Vomiting  
Patients who experience nausea and vomiting in association with APR -246 infusion will be 
prescribed appropriate rescue treatment and prophylaxis (e.g., anti -nausea or anti -emetics 
medication) as per institutional guidelines. Patients who receive additional drugs that are 
known to cause QT interval prolongation must be mon itored for any signs of QT interval 
prolongation via an ECG before and after the APR -246 infusion.  
 
• If QTc >501 msec is observed in a patient concomitantly treated with another QT 
interval prolonging drug, this drug should be stopped and treatment with APR -246 
may be restarted when QTc <470 msec or baseline measurement in patients with pre -
existing BBB and/or pacemaker (refer to Section  6.3.1 ). 
 
A list of suggested rescue medications is provided below in Table 5. 
Table 5. Medications for Managements of Nausea and Vomiting  
Drug  Dosage  QT Interval 
Prolongationa 
Ondansetron  8 mg PO administered 30 minutes before the start 
of infusion or per label  Yes 
Dolasetron  100 mg PO administered within one  
hour before start of infusion or per label  Yes 
Palonosetron  0.25  mg IV administered over 30 seconds 
beginning approximately 30 min prior to the start 
of infusion on Day 1 only  No 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 56 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Prochlorperazine  10 mg PO three times daily. Continue until the end 
of Day 4 of the cycle. When used prophylactically 
in subsequent cycles, start the day prior to Day 1 
administration of APR -246 No 
a Please refer to Section 6.3.1  for details on co ncurrent administration of medications known to cause QTc 
interval prolongation.  
 
6.3.4  Management of Infusion Reactions  
If a patient experiences an infusion reaction during the study, the infusion will be stopped 
and appropriate medical care (e.g., epinephrine , oxygen, H1 and H2 antagonists, and/or 
corticosteroids) will be administered57. 
 
  
 
 
 
 
 
 
  
The following recommendatio ns were taken from National Comprehensive Cancer Network 
Guidelines for Prevention and Treatment of Cancer -Related Infections (Version 1.2021).  
 
Table 6. Recommendations for prevention and treatment of cancer -related infections  
Organism  Recommendations  
Bacterial  Consider fluoroquinolone or other suitable anti -bacterial prophylaxis during 
neutropenia  
Fungal  Consider prophylaxis during neutropenia and for anticipated mucositis. Assess risk for 
Pneumocystis jirovecii pneumonia (PJP) and select agent(s) as clinically indicated.   
Viral  Start treatment with anti -viral medication in the setting of neutropenia and  continually 
assess the risk for viral infection during treatment with anti -cancer therapy.  
 
Please refer to Section 6.2 Dose Interruptions/Withholding, for guidance on APR -246 dose 
modification in the setting severe infection and/or infestation event(s).    
 
Refer to Section 6.4 Concomitant Treatment, for a description of drugs that are not allowed 
to be used while a patient is on study treatment.  
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 57 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6.3.6  Management of Neutropenia with or without Fever  
Monitor complete blood counts at the time of study enrollment and throughout the course 
of study treatment. Supportive measures such as antimicrobials for prophylaxis or in the 
setting of prolonged myelosuppression, and/or at the first signs of infection a re 
recommended to reduce the risk of a serious or severe infection that may lead to a fatal 
outcome in the setting of neutropenia with or without fever (see Section 6.3.5 ).   
 
Myeloid growth factors may be used in the setting of severe or prolonged neutropenia. Refer 
to Section 6.4 Concomitant Trea tment, for a description of drugs that are not allowed to be 
used while a patient is on study treatment.  
 
Please refer to Section 6.2 Dose Interruptio n/Withholding  for guidance on APR -246 dose 
modification in the setting neutropenia with or without fever.    
 
6.3.7  APR -246 Dose Modification in the Setting of Moderate Renal Impairment  
APR-246 is partially eliminated via the kidney and moderate renal impairment, defined by a 
creatinine clearance, or estimated glomerular filtration rate value of >30 to <60 mL/min, can 
lead to increases in plasma levels of approximately 30%. Therefore, for patients with 
moderate renal impairment, the dose of APR -246 shou ld be reduced by 33% from the 
current dose ( Table 7). 
 
Table 7: APR -246 Dose Modification in the Setting of Moderate Renal Impairment  
APR -246 Dose  33% Reduced Dose  Loading Dose (over 
45 min)  Maintenance Dose 
(over 5 hr and 15 min)  
4.5 g  3.0 g  1.0 g  2.0 g  
4.0 g  2.7 g  0.9 g  1.8 g  
3.5 g  2.3 g  0.8 g  1.5 g  
3.0 g  2.0 g  0.7 g  1.3 g  
<3.0 g  Please consult with Medical Monitor  
 
Monitoring renal function by assessment of serum creatinine prior to infusion of APR -246 is 
recommended in all patients.  
 
6.3.8  Venetoclax Dose Adjustments  
Please refer to venetoclax USPI 37 for recommended dose modifications.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 58 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6.3.9  Azacitidine Dose Adjustments  
Missed doses (for any reason but toxicity) may, at the Investigator’s decision, be 
compensated by adding an additional dosing day for azacitidine (e.g. Day 8) so that the 
patient receives the total 7 days of treatment per cycle.  
 
If unexplained reductions in serum bicarbonate levels to less than 20 mEq/L occur during 
treatment with azacitidine, contact the study  medical monitor to discuss if a reduction in 
azacitidine dose by 50% should occur with the next scheduled cycle.  Similarly, if unexplained 
elevations in BUN or serum creatinine occur, contact the study medical monitor to discuss if 
a delay in the next cy cle of azacitidine is warranted and/or a reduction in azacitidine dose by 
50% should occur with the next scheduled cycle.   
 
Please refer to azacitidine USPI58 for recommended dose modifications.  
 
6.3.10  Antifungal Prophylaxis  
Antifun gal agents may be used at the investigator’s discretion and with appropriate 
monitoring of the QTc and adjustment of the venetoclax dose.  
 
6.4 Concomitant Treatment  
Patients must not receive any other concurrent anti -cancer therapy, including investigational  
agents while on study treatment. Please also see Section 2.3, regarding known drug -drug 
interactions for venetoclax, and the importance of avoiding c ertain food such as grapefruits. 
This is important both for patient safety and for enabling a correct assessment of an unlikely 
drug -drug interaction between the study drug APR -246 and venetoclax. For patients 
concomitantly treated with strong or moderate CYP3A inhibitors, or P -gp inhibitors, the dose 
of venetoclax should be determined based on institutional practice and current prescribing 
information. Strong or moderate CYP3A inducers should be avoided (see APPENDIX VII I). 
 
Patients may continue their baseline medication(s) as long as they are not prohibited. 
Palliative and supportive care (e.g., anti -emetics, bisphosphonates) for disease -related 
symptoms will be offered to all patients in the study per institutional practices. AEs will be 
treated as clinically indicated. All concomitant medications that are currently in use or that 
become necessary during the study should be recorded.  
 
If the patient develops an acute infusion reaction (  Grade 2), the i nfusion must be stopped 
until the reaction is resolved to ≤ Grade 1. Premedication (e.g., systemic corticosteroids) may 
be used after the first cycle.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 59 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Use of myeloid growth factors is allowed at the discretion of the investigator per institutional 
practic es. If patients experience prolonged myelosuppression, they should be placed on 
infection prophylaxis per standard of care.  
 
Hydroxyurea may be used for control of leukocytosis.  
 
6.5 Monitoring Patient Compliance  
This study will be monitored by Aprea Therapeut ics, Inc. or its CRO according to ICH E6 
guidelines of GCP. The study site monitor will regularly visit the study sites to ensure that the 
study is conducted according to the protocol and GCP principles. All instances of protocol 
deviations will be entered  and reviewed by the Investigator, Sponsor and appropriate 
 designee.  
 
 
7.0 STUDY EVALUATIONS  
 
7.1 Schedule of Study Evaluations  
Study evaluations are summarized in Table 8 and described in Sections 7.2 through 7.4. 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 60 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Table 8: Study Calendar  
Study Calendar  
Evaluation a 
 
 Screeninga  Cycle 1   Cycle 2 and Subsequent Cycles  End of 
Odd 
Cycles  End of 
Even 
Cycles  End of  
Treat -
ment 
r Long -
Term 
Follow
-Up s D1 D2 D3 D4 D 
5-7 D8 
b D 
15b D 
22b D 23  D1
c D
2 D3 D4 D 
5-7 D8 
b D15
b D22
b D23
b 
Informed consent  ×                       
TP53  mutation by central lab  d ×                       
Medical history e ×                       
Physical examination f × ×         ×           ×  
Height  ×                       
Weight  × ×         ×           ×  
Vital signs f × × × × ×      × × × ×        ×  
ECOG PS  × ×         ×           ×  
APR-246 g  × × × ×      × × × ×          
Venetoclax h  × × × × × × × × × × × × × × × × × ×     
Azacitidine i  × × × × ×     × × × × ×         
Bone marrow /peripheral blood 
collection j ×        ×            × × × 
Response assessment  k         ×           × ×   
Hematology l × ×     × × ×  ×j     × × ×    × × 
Blood chemistry m × ×     × × ×  ×     × × ×    ×  
Pregnancy test n ×                       
ECG o  × ×o ×o ×o ×o      ×             
TLS lab monitoring p  × ×                     
APR-246 PK sample q  × ×  ×         ×          
Venetoclax PK sample q  × ×      × ×    ×          
Survival                       × × 
Clinical toxicity assessment   Starting at the time of study treatment initiation through 30 days after last dose t  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 61 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Study Calendar  
Evaluation a 
 
 Screeninga  Cycle 1   Cycle 2 and Subsequent Cycles  End of 
Odd 
Cycles  End of 
Even 
Cycles  End of  
Treat -
ment 
r Long -
Term 
Follow
-Up s D1 D2 D3 D4 D 
5-7 D8 
b D 
15b D 
22b D 23  D1
c D
2 D3 D4 D 
5-7 D8 
b D15
b D22
b D23
b 
Concomitant medications  × Reviewed  throughout  study   

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 62 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Footnotes to Study Calendar  
 
a. All screening/baseline evaluations are performed within 28 days prior to the start of study 
treatment. In the event that a visit or test cannot be scheduled on the exact visit day, a window of 
±3 days is allowable.  
b. A window of ±3 days applies to this study visit.  
c. After the first cycle, Day 1 evaluations of subsequent c ycles are to be done within 3 days prior to 
next cycle drug administration.  
d. A bone marrow aspirate in ethylenediaminetetraacetic acid  (EDTA ) and peripheral blood sample 
in EDTA is required at the time of consent and screening for central lab TP53  mutation 
determination . If the bone marrow aspirate  cannot be obtained due to a dry tap , peripheral blood 
alone can be used for TP53  mutation status for enrollment.  If local TP53  mutation and/or p53 IHC 
results become available before central TP53  mutation results, enrollment may be made based on 
local results with Medical Monitor approval . 
e. Full medical history is obtained at screening for safety and eligibility purposes; this will include any 
clinically significant findings from 28 days prior to s creening date.  
f. Physical exam and vital signs (including blood pressure, heart rate, respiration rate and 
temperature) are completed for safety purposes and clinically significant items are recorded as 
AEs where appropriate. Vital signs are collected prior to APR -246 infusion, 2 hours into infusion 
and at EOI (±30 minutes at all time points).  
g. APR-246 is administered IV on days 1 –4 of each 28 -day cycle.  
h. Only in cohorts with venetoclax: Venetoclax is given orally at the dose of 400 mg (4 tablets) once 
daily at  approximately the same time every day, with a meal and water. On days 1 – 4 of Cycles 1 
and 2 it is recommended that venetoclax is taken approximately one hour after start of APR -246 
infusion. If a prophylactic antifungal agent is administered concurrentl y, the daily dose of 
venetoclax should be determined based on institutional practice and current prescribing 
information for venetoclax.  
i. Only in cohorts with azacitidine.  Azacitidine is administered subcutaneously over 7 consecutive 
days, on Days 1 -7 of ea ch 28 -day cycle. On Days 1 –4 azacitidine is administered immediately after 
the APR -246 infusion. Subcutaneous route is preferred but azacitidine may be administered 
intravenously at the Investigator’s discretion. The same route should be maintained over th e 7-day 
treatment period.  
j. Bone marrow aspirate sample is collected at baseline and when bone marrow is sampled for 
disease assessment. If no aspirate is available  due to a dry tap , then peripheral blood is 
acceptable..  
k. Initial response assessment (blasts percentage) is performed on Day 22 (±3 days). In patients with 
bone marrow hypocellularity, venetoclax may need to be held and restarted after recovery of 
blood counts (ANC ≥0.5 × 109/L, and platelets ≥25 × 109/L), confirmed by repeat bone marrow 
biopsy on  approximately Day 35 and following discussion with Medical Monitor. For subjects who 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 63 of 103 28 Octo ber 202 1 
Confidential - Entire Page  require a delay in study treatment for peripheral blood count recovery after a bone marrow 
evaluation, hematology values for up to 4 weeks from the bone marrow analysis c an be used to 
determine the IWG response. Ongoing response assessments should be performed at the end of 
each cycle (every 4 weeks) starting at Cycle 2, based on peripheral blood and bone marrow sample 
(at the end of even cycles), and peripheral blood samp le alone (at the end of odd cycles). After the 
first year of the study treatment response assessment will be performed every two months. 
Following a documented CR, a bone marrow aspirate/biopsy is not required if the response 
assessment can be made based o n the peripheral blood, except at the time of suspected relapse 
at which time a bone marrow aspirate/biopsy is required.  
l. Hematology, including complete blood count with white blood cell differential, weekly. Additional 
peripheral blood sample should be co llected on Day 1 of each cycle starting at Cycle 2 for disease 
assessment, if bone marrow aspirate is not available.  
m. Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, blood urea nitrogen 
(BUN), creatinine, glucose, calcium, albumin, t otal protein, total bilirubin, AST, ALT, alkaline 
phosphatase weekly. At screening, the creatinine clearance may be calculated from the serum 
creatinine. A 24 -hour urine for creatinine clearance may be performed at Investigator’s discretion.  
n. Serum or urine βhCG must be performed within 7 days prior to study treatment initiation in 
female patients of childbearing potential.  
o. Standard 12 -lead ECGs in triplicate at screening, on Days 1 –4 of Cycle 1 and on Days 1 of each 
subsequent cycle with patient in a s emi-recumbent position . Please consult Table 12 for ECG 
collection schedule.  
p. Only in cohorts with venetoclax: Potassium, phosphorus, calcium and uric acid  should be evaluated 
approximately 6 -8 hr and 24 hr (± 4 hr) after the initial administration of venetoclax in order to 
monitor for potential development of TLS . 
q. Please consult Section 8.4 for PK collection schedule.  
r. Patients discontinuing treatment should complete their end of treatment visit within 
approximately 28 days of their last dose of APR -246. Physical exam, vital signs, clinical toxicity 
assessment, hematology, serum chemistry and bone marrow aspirate and bio psy with NGS 
analysis should be performed, if feasible.  
s. Long -term follow up can be done remotely (e.g. via telephone, via local practitioner or via review 
of medical records). Assuming there is no withdrawal of consent, patients who stop study 
treatment for any reason (e.g. toxicity, transition to SCT, PD) will  continue long -term follow -up (see 
Section 7.4). If a patient is removed from the study due to unacceptable AEs, the event(s) will be 
followed until  resolution or stabilization of the AE.  Off-treatment data on overall survival will be 
updated every month (i.e. every 28 days ±3 days) or until death or withdrawal of consent for study 
participation, whichever occurs first. If a patient is removed from th e study due to unacceptable 
adverse events (AEs), the event(s) will be followed until resolution or stabilization of the adverse 
event. Patients who respond and discontinue study treatment for reasons other than PD should 
have response assessments and surv ival should be collected every month until relapse, death or 
withdrawal of consent for study participation, whichever occurs first. After relapse, data for 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 64 of 103 28 Octo ber 202 1 
Confidential - Entire Page  survival should be collected every month (i.e. every 28 days ±3 days) until death or withdrawal of 
consent for study participation, whichever occurs first.  
t. AE description, grade and start date and resolution date should be documented.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 65 of 103 28 Octo ber 202 1 
Confidential - Entire Page  7.2 Pre-Study Assessments  
Prior to performing any procedures or assessments, the nature of the study and the 
potent ial risks associated with the trial will be explained to all patient candidates and written 
informed consent will be obtained. Patients who choose to participate will have to consent 
to the biobanking program and will be asked to sign the mandatory section  in the main study 
consent form related to biobank samples. Evaluations obtained as part of routine medical 
care and performed during the screening period may be used in place of the study specific 
evaluations. Patients will acknowledge and agree to the po ssible use of this information for 
the study by giving informed consent.  
 
7.2.1  Screening  
All screening evaluations are to be performed within approximately 28 days of study 
treatment initiation, unless otherwise noted.  
• Signed written informed consent  
• TP53  mutation determination  by central lab . Bone marrow aspirate in EDTA and 
peripheral blood samples in EDTA submitted to central lab.  The peripheral blood 
sample may be submitted alone in cases where the aspirate is not o btainable due to 
a dry tap. If local TP53  mutation and/or p53 IHC results become available before 
central TP53  mutation results, enrollment may be made based on local results with 
Medical Monitor approval . 
• Medical history  
• Physical examination  
• Height  
• Weigh t  
• ECOG performance status ( APPENDIX III ) 
• Vital signs, including blood pressure, heart rate, respiration rate and temperature  
• Hematology, including complete blood count with white blood cell differential.  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphata se.  
• Creatinine clearance (Cockcroft -Gault method; APPENDIX II ) 
• Serum or urine βhCG must be performed within 7 days prior to study treatment 
initiation for female patients of childbearing potential.  
• ECG: standard 12 -lead ECGs with patient in a semi -recumbent position in triplicate.  
• Concomitant medication review  
• Baseline bone marrow aspirate for exploratory objectives. If no aspirate is available, 
then peripheral blood is acceptable.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 66 of 103 28 Octo ber 202 1 
Confidential - Entire Page  7.2.2  Cycle 1  
7.2.2.1  Cycle 1 Days 1 -7  
Day 1 examinations marked * do not need to be repeated if already performed within 3 days 
prior to day 1 cycle 1.   
• Clinical toxicity assessment  
• Concomitant medications review  
• Physical examination: Day 1*  
• Weight: Day 1* 
• ECOG performance status (Day 1*; APPENDIX III ) 
• Vital signs, including blood pressure, heart rate, respiration rate and temperature, 
collected 2 hours into APR -246 infusion (± 30 min) and at EOI (± 30 min)  
• Hematology (Day 1*), including complete blood cou nt with white blood cell 
differential  
• Serum chemistry (Day 1*), including sodium, potassium, chloride, magnesium, CO 2, 
BUN, creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, 
alkaline phosphatase  
• ECG: standard 12 -lead ECG with  patient in a semi -recumbent position; pre -dose (prior 
to the APR -246 PK blood draw before the infusion) and at the EOI, per Table 12 
• APR-246 administratio n: Days 1 – 4 
• Blood sample for APR -246 pharmacokinetics: on Days 1, 2 and 4, per Table 9 
• Only in cohorts with venetoclax. Venetoclax administration: once daily, at 
approximately the same time every day. On days 1 – 4 it is recommended that 
venetoclax is taken with a meal and water approximately one hour after start of 
APR-246 infusion. If no p rophylactic antifungal agent is  administered  concurrently, 
the ramp -up phase should consist of 100, 200, and 400 mg of venetoclax once daily 
given on days 1, 2, and 3 of Cycle 1, respectively. If a p rophylactic antifungal agent is  
administered concurrently, the ramp -up and maintenance dose of veneto clax should 
be determined based on institutional practice and current prescribing information for 
venetoclax  
• Only in cohorts with venetoclax. Blood sample for venetoclax pharmacokinetics in the 
presence of APR -246 ( Table 10) 
• Only in cohorts with venetoclax. TLS lab monitoring: potassium, phosphorus, calcium 
and uric acid should be evaluated 6 – 8 hr and 24 hr (± 4 hr) after the initial 
administration of v enetoclax in order to monitor for potential development of TLS  
• Azacitidine administration, only in cohorts with azacitidine . Administered daily for 7 
consecutive days starting on Day 1 (Days 1 to 7 inclusive). The same route should be 
maintained over the 7 -day treatment period. On Days 1 -4 azacitidine is given 
immediately after APR -246 infusion  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 67 of 103 28 Octo ber 202 1 
Confidential - Entire Page  7.2.2.2  Cycle 1 Day 8 (±3 Days)  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell differential  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatas e 
• Only in cohorts with venetoclax. Venetoclax administration: 400 mg (4 tablets) once 
daily, at approximately the same time every day, with a meal and water. If a 
prophylactic antifungal agent is administered concurrently, the daily dose of 
venetoclax shou ld be determined based on institutional practice and current 
prescribing information for venetoclax  
 
7.2.2.3  Cycle 1 Day 15 (±3 Days)  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell differential  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatas e 
• Only in cohorts with venetoclax. Venetoclax administration: 400 mg (4 tablets) once 
daily, at approximately the same time every day, with a meal and water. If a 
prophylactic antifungal agent is administered concurrently, the daily dose of 
venetoclax shou ld be determined based on institutional practice and current 
prescribing information for venetoclax  
 
7.2.2.4  Cycle 1 Day 22 (±3 Days)  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell diff erential  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatase  
• Only in cohorts with venetoclax. Blood sample for venetoclax pharma cokinetics in the 
presence of APR -246 ( Table 10) 
• Bone marrow sample for response assessment (blasts percentage). In patients with 
bone marrow hypocellul arity, venetoclax may need to be held and restarted after 
recovery of blood counts (ANC ≥0.5 × 109/L, and platelets ≥25 × 109/L), confirmed by 
repeat bone marrow biopsy on Day 35 and following discussion with Medical Monitor.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 68 of 103 28 Octo ber 202 1 
Confidential - Entire Page  7.2.2.5  Weekly Assessments  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell differential  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatase  
 
7.2.3  Cycle 2 Day 1 ±3 Day and Onwards (Cycle 3+)  
These tests should be performed prior to first dose  
• Clinical toxicity assessment  
• Concomitant medications review  
• Physical examination: Day 1*  
• Weight  
• ECOG performance status (Day 1; APPENDIX III ) 
• Vital signs  
• Hematology (Day 1*), including complete blood count with white blood cell differential  
• Serum chemistry (Day 1*), including sodium, potassium, chloride, magnesium, CO 2, 
BUN, creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, 
alkaline phosphatase  
• ECGs: see  Table 12 
 
7.2.3.1  Cycle 2 Days 1 -7  
• Clinical toxicity assessment  
• Concomitant medications review  
• Vital signs, including blood pressure, heart rate, respiration rate and temperature, 
collected 2 hours into APR -246 infusion (± 30 min) and at EOI (± 30 min)  
• Only in cohorts with v enetoclax. Venetoclax administration: 400 mg (4 tablets) once 
daily, at approximately the same time every day, with a meal and water. If a 
prophylactic antifungal agent is administered concurrently, the daily dose of 
venetoclax should be determined based o n institutional practice and current 
prescribing information for venetoclax. Note : Day 4 of Cycles 2 –5 only: Blood sample 
for venetoclax pharmacokinetics in the presence of APR -246 ( Table 10) 
• APR-246 administration: Days 1 – 4 
• Azacitidine administration, only in cohorts with azacitidine . Administered daily for 7 
consecutive days starting on Day 1 (Days 1 to 7 inclusive). The same route should be 
maintained over the 7 -day treatment period. On Days 1 -4 azacitidine is given 
immediately after APR -246 infusion  
• Blood sample for APR -246 pharmacokinetics: on Day 4, per Table 9. Samples for APR -
246 to be taken 1 -3 hours after completion of APR-246 administration.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 69 of 103 28 Octo ber 202 1 
Confidential - Entire Page  • ECG: standard 12 -lead ECGs with patient in semi -recumbent position prior to the PK 
blood draw before APR -246 in fusion on Day 1, per  Table 12 
 
7.2.3.2  Cycle 2 Day 8 (±3 Days)  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell differential, weekly  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatase, weekly  
• Only in cohort s with venetoclax. Venetoclax administration: 400 mg (4 tablets) once 
daily, at approximately the same time every day, with a meal and water. If a 
prophylactic antifungal agent is administered concurrently, the daily dose of 
venetoclax should be determined  based on institutional practice and current 
prescribing information for venetoclax  
 
7.2.3.3  Cycle 2 Day 15 (±3 Days)  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell differential, weekly  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatase, weekly  
• Only in cohorts with venetoclax. Venetoclax administration: 400 mg (4  tablets) once 
daily, at approximately the same time every day, with a meal and water. If a 
prophylactic antifungal agent is administered concurrently, the daily dose of 
venetoclax should be determined based on institutional practice and current 
prescribin g information for venetoclax  
 
7.2.3.4  Cycle 2 Day 22 (±3 Days)  
• Clinical toxicity assessment  
• Concomitant medications review  
• Hematology, including complete blood count with white blood cell differential, weekly  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatase, weekly  
• Only in cohorts with venetoclax. Venetoclax administration: 400 mg (4 tablets) once 
daily, at approximately the sam e time every day, with a meal and water. If a 
prophylactic antifungal agent is administered concurrently, the daily dose of 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 70 of 103 28 Octo ber 202 1 
Confidential - Entire Page  venetoclax should be determined based on institutional practice and current 
prescribing information for venetoclax  
 
7.2.4  End of Odd Numbe red Cycles  
• Response assessment, based on peripheral blood (blasts percentage)  
 
7.2.5  End of Even Numbered Cycles  
• Bone marrow  sample for response assessment (blasts percentage)  
• Bone marrow aspirate for exploratory objectives (if no aspirate is available, then 
peripheral blood is acceptable)  
 
7.3 End of Treatment Visit  
This visit should take place within 28 days of the last dose of study treatment, if treatment is 
stopped early for any reasons.   
 
• Physical examination  
• Weight  
• Vital signs  
• Disease asse ssment  
• Bone marrow aspirate for exploratory objectives. If no aspirate is available, then 
peripheral blood is acceptable  
• ECOG performance status ( APPENDIX III ) 
• Hematology, including complete blood count with white blood cell differential  
• Serum chemistry, including sodium, potassium, chloride, magnesium, CO 2, BUN, 
creatinine, glucose, calcium, albumin, total protein, total bilirubin, AST, ALT, alkaline 
phosphatase  
• Clinical toxicity assessment up to 30 days after the last dose  
 
7.4 Long -Term Follow -Up 
Long -term follow -up can be done remotely (e.g. via telephone, via local practitioner or via 
review of medical records).  After a patient is removed or withdrawn from the study, the 
patient will be followed until death or withdrawal of consent for study participation. Off -
treatment data on overall survival will be updated every month (i.e. every 28 days ±3 days) 
or until dea th, whichever occurs first. If a patient is removed from the study due to 
unacceptable AEs, the event(s) will be followed until resolution or stabilization of the AE. 
Patients who respond and discontinue study treatment for reasons other than PD should 
have response assessments and survival should be collected every month until relapse or 
death, whichever occurs first. After relapse, data for survival should be collected every month 
until death  or withdrawal of consent for study participation, whichever occ urs first . 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 71 of 103 28 Octo ber 202 1 
Confidential - Entire Page   
8.0 STUDY ASSESSMENTS  
8.1 Safety Assessments  
8.1.1  Safety Analysis  
Safety data will be tabulated for all patients and include vital signs, laboratory parameters, 
and AEs.  
 
8.1.2  Reporting of Adverse Events  
8.1.2.1  Adverse Events  
An AE is any untoward medical occurrence in  a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship 
with the treatment. An AE can be any unfavorable and unintended sign (including a 
laboratory finding), symptom or diseas e temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product.  
 
The treatment -emergent AE reporting period starts at study treatment initiation. All 
treatment -emergent AEs will be collected for up to 30 days after the last dose of study 
treatment. At each evaluation, patients should be interviewed in a non -directed manner to 
elicit potential adverse reactions from the patient. The occurrence of an AE will be based on 
changes  in the patient’s physical examination, laboratory results, and/or signs and 
symptoms.  
 
On Cycle 1, Day 1, any events observed from the time of signing informed consent but prior 
to initial study drug administration will be recorded as a serious or non -serious adverse 
event, if considered by the Investigator to be causally related to a study -required procedure 
or activity that was conducted prior to Cycle 1, Day 1 (i.e., screening period). Events observed 
from the time of signing informed consent, but prior  to initial study drug administration that 
are not considered to be causally related to a study -required procedure or activity should be 
recorded on the medical history CRF page.  
 
All AEs (except Grade 1 and 2 laboratory abnormalities that do not require an intervention), 
regardless of causal relationship, are to be recorded in the CRF and source documentation. 
The Investigator must determine the intensity of any AEs according to th e NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0 and their causal relationship. 
Those AEs not covered by these criteria will be graded as follows:  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 72 of 103 28 Octo ber 202 1 
Confidential - Entire Page  1. Mild: Discomfort noticed, but no disruption of normal daily activity. Prescripti on drug 
not ordinarily needed for relief of symptom but may be given because of personality 
of patient.  
2. Moderate: Discomfort sufficient to reduce or affect normal daily activity. Patient is 
able to continue in study; treatment for symptom may be needed.  
3. Severe: Incapacitating, severe discomfort with inability to work or to perform normal 
daily activity. Severity may cause cessation of treatment with test drug; treatment for 
symptom may be given and/or patient hospitalized.  
4. Life-Threatening: Symptom (s) place the patient at immediate risk of death from the 
reaction as it occurred; it does not include a reaction that, had it occurred in a more 
serious from, might have caused death.  
5.  Fatal: Event caused the death of the patient.  
 
AEs will be followe d until resolution or stabilization while the patient remains on -study. Once 
the patient is removed from study, events thought to be related to the study medication will 
be followed until resolution or stabilization, unless, in the Investigator’s opinion t he event is 
unlikely to resolve due to the patient’s underlying disease, or until the patient starts a new 
treatment regimen or the patient is lost to follow -up. 
 
8.1.2.2  Attribution Definitions  
An AE is considered to be associated with the use of the study treatment if the attribution is 
determined as possible, probable or definite. Attribution of AEs will be recorded in the CRF 
as: 
 
• Unrelated: The AE is clearly not related to the study treatment.  
• Unlikely: The AE is doubtfully related to the study treatment . 
• Possible: The AE may be related to the study treatment.  
• Probable: The AE is likely related to the study treatment.  
• Definite: The AE is clearly related to the study treatment.  
 
8.1.2.3  Definition of an Unexpected Adverse Event  
An unexpected AE is defined as any a dverse drug experience, the specificity or severity of 
which is not consistent with the current Investigator Brochure; or, if an Investigator Brochure 
is not available, the specificity or severity of which is not consistent with the risk information 
descri bed in this protocol or in the regulatory agency study authorization application.   
 
For study treatments used in this protocol that have been approved for use in the US by the 
FDA (i.e., venetoclax, and azacitidine), the reference safety information that will be used for 
making expectedness decisions is the most current version of the product USPI that can be 
found on the FDA website.   
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 73 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Unexpected, as used in this definition, refers to an adverse drug experience that has not 
been previously observed (e.g., included in the Investigator’s Brochure or USPI, as applicable) 
rather than from the perspective of such experience not being anticipated from the 
pharmacological properties of the pharmaceutical product.  
 
8.1.2.4  Serious Adverse Event (SAE)  
A seri ous adverse event is defined as any untoward medical occurrence that at any dose:  
 
1. Results in death,  
2. Is life -threatening (i.e., the patient was at risk of death at the time of the event. It does 
not refer to an event which hypothetically might have c aused death if it was more 
severe),  
3. Requires in -patient hospitalization or prolongation of existing hospitalization 
excluding that for pain management, disease staging/re -staging procedures, or 
catheter placement unless associated with other serious eve nts, 
4. Results in persistent or significant disability/incapacity, or  
5. Is a congenital anomaly/birth defect.  
 
Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious adverse drug e vents when, based on appropriate 
medical judgment, they may jeopardize the patient and may require medical or surgical 
intervention to prevent one of the outcomes listed above.  
 
8.1.2.5  Pregnancy  
Any pregnancy detected during the study, or that occurs within 30 da ys after stopping study 
medication, must be reported immediately to the Investigator. Pregnancy, in and of itself, is 
not regarded as an AE, unless there is suspicion that study medication may have interfered 
with the effectiveness of a contraceptive medic ation. If the patient becomes pregnant while 
on-study, the study drug should be immediately discontinued. Pregnancy information about 
a female patient or a female partner of a male patient should be reported immediately from 
the time the Investigator first  becomes aware of a pregnancy or its outcome. This will be 
performed by the Investigator per instructions from the Sponsor’s monitoring CRO.   
 
Any pregnancy complication, spontaneous abortion, elective termination of a pregnancy for 
medical reasons, outcom e of stillbirth, congenital anomaly/birth defect, or serious adverse 
event in the mother will be recorded as an SAE and will be reported as described in Section 
8.1.2.6 .  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 74 of 103 28 Octo ber 202 1 
Confidential - Entire Page  8.1.2.6  Reporting of Serious Adverse Events  
AEs classified as serious require expeditious handling and reporting to Sponsor’s monitoring 
CRO to comply with regulatory requirements.  
 
For any serious adverse event (SAE) that occurs while a patient is on -study; within 30  days of 
the last study treatment administration, regardless of any opinion as to the relationship of 
the SAE to the study treatment; or if any SAE that the Investigator feels is related to the study 
treatment occurs later tha n 30  days after the last study treatment administration, the 
Sponsor’s monitoring CRO must be notified immediately (within 24  hours of becoming aware 
of the event) by electronic data capture (EDC) system, email, fax or telephone. Notification 
by email is p referred. The primary mechanism for reporting an SAE to the sponsor will be 
the electronic data collection tool. An SAE eCRF should be completed in the electronic data 
capture (EDC) system within 24 hours of site becoming aware of the event. EDC Alerts wil l be 
sent to Safety desk for all SAEs.  
 
If the EDC system is inaccessible/unavailable, then the site will use the paper SAE form in 
order to report the SAE within 24 hours. Emailing the paper SAE forms is the preferred 
method of notification.  
 
SAEs will be reported to: Email:  
 
8.1.2.7  Safety Monitoring Plan  
The medical monitor is responsible for ongoing safety monitoring for the study per the 
detailed safety plan. This monitoring will include a review of all serious AEs as they are  
reported by the study site. The medical monitor will also be in contact with site monitors and 
will be available to discuss any issues concerning safety with site staff. Safety data will be 
reviewed periodically by  and the Sponsor  Medical Officer.  
 
DRT consisting of the Medical Monitor, Site Principal Investigators, and other clinical research 
personnel that the Sponsor may deem appropriate, will hold DRM on an interim basis at a 
frequency dependent on study accrual. At these meeti ngs, the DRT will review AEs and DLTs 
and make recommendations regarding the RP2D. In the expansion portion of the study, the 
DRT will evaluate safety and tolerability after 5 patients have completed 1 cycle of treatment 
in each cohort. All accumulated saf ety data will be discussed during DRMs.  
 
The DRT will produce summaries or minutes of these meetings. These summaries will be 
available for inspection when requested by any of the regulatory bodies charged with the 
safety of human subjects and the integrit y of data.  
 

Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 75 of 103 28 Octo ber 202 1 
Confidential - Entire Page  8.2 Efficacy Assessments  
8.2.1  Complete Remission Rate  
CR rate will be defined as the proportion of patients who achieve CR.  
 
8.2.2  Duration of Response  
DoR will be measured from the time of initial response to disease relapse/progression or 
death.  
 
8.2.3  Overall Response Rate  
Overall response rate (ORR) will be defined as the proportion of patients achieving CR, CRi, 
complete remission with CRp, partial remission (PR) and MLFS by the IWG 2003 AML criteria 
(APPENDIX I ). 
 
8.2.4  Overall Surv ival 
Overall survival (OS) is defined for all enrolled patients, as measured from the date of 
enrollment until the date of death.  
 
8.2.5  Stem Cell Transplant  
Patients may go on to receive SCT and this is likely to be a reflection of a positive outcome to 
treatm ent. The primary approach will be to use a treatment policy strategy (ICH E9 (R1) 
addendum) where patients who receive SCT will continue to be followed for OS and relapse 
from any response with their date of death/relapse used in the analysis. If for any r eason a 
patient receives SCT prior to a documented CR they will not be counted as a response. 
Sensitivity analyses may be performed as counting post -SCT CR/PR as a response.   
 
8.3 Progression -Free Survival (PFS)  
Progression -free survival  (PFS) is defined  for each patient  as the time  from start  of treatment  
to the  date of the first documented  progression  or death due  to any  cause.  Patients  who die  
without  a reported  prior progression  will be considered  to have  progressed  on the  date  of 
their death.  Patients  who  did not progress  or die will be  censored  on the  date of their last  
evaluable  tumor  assessment.  Patients  who  started  any subsequent therapy  without  a prior  
reported  progression  will be censored  at the last evaluable  tumor assessment  prior to the  
initiation of  the subsequent  anticancer therapy.  
 
8.4 Pharmacokinetics  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 76 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Plasma concentrations of APR -246 will be measured in Cycle 1, at the timepoints provided in 
Table 9. Please refer to sections 2.3 and 6.4, regarding the risk of certain drugs and foods 
influencing the PK of venetocla x such as grapefruits (see APPENDIX VII ). This is important 
both for patient safety and for enabling a correct assessment of an unlikely drug -drug 
interaction between the study drug APR -246 and venetoclax from PK samples.   
Table 9. PK Blood Sampling Timepoints for APR -246 
APR -246 plasma collection timepoints a Cycle 1   
Subsequent 
Cycles  
D1 D2 D4 D4 
Prior to APR -246 infusion  × × × × 
At the end of APR -246 infusion  ×  × × 
1 hour after the end of APR-246 infusion  ×  × × c 
3 hours after the end of APR -246 infusion 
b ×    
a A window of ±15 min applies to each time point.  
b Samples are collected as part of the venetoclax PK sampling scheme below ( Table 10). A single PK sample 
should be drawn and split into 2 samples for analysis of both drugs at these timepoints.  
c Sample collected  between 1 and 3 hours after the end of infusion.  
 
Only in cohorts with venetoclax, plasma concentrations of venetoclax will be measured in 
Cycle 1, at the timepoints provided in Table 10, and then prior to venetoclax administration 
on Day 4 of Cycles 2 – 5 (Table 11). 
 
Table 10. PK Blood Sampling Timepoints for Venetoclax in Cycle 1  
Venetoclax plasma collection timepoints  D1 D2 D22 D23 
Prior to venetoclax administration a × × × × 
2 hours following venetoclax administration 
b x  x  
3 hours following venetoclax administration 
c ×  ×  
4 hours following venetoclax administration 
d ×  ×  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 77 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6 hours following venetoclax administration 
e ×  ×  
8 hours following venetoclax administration f ×  ×  
 
a Baseline sample collected prior to venetoclax administration. On Day 1, it is recommended that 
venetoclax is given 1 hour after the start of APR -246 infusion (±10 min), following a meal that will start 
approximately 15 minutes after initiation of APR -246 infusion. On Day 1, the baseline sample prior to 
APR-246 infusion can be split into two samples and used as pre -dose sample for venetoclax as well. 
b 3 hours following initiation of APR -246 infusion on Day 1 (±15 min)  
c 4 hours following initiation of APR -246 infusion on Day 1 (±15 min)  
d 5 hours following initiation of APR -246 infus ion on Day 1 (±15 min)  
e 7 hours following initiation of APR -246 infusion on Day 1 (±15 min). This blood draw is also used for 
the 3rd sample for APR -246 measurements ( Table 10; 1 hour after EOI).  
f 9 hours following initiation of APR -246 infusion on Day 1 (±30 min). This blood draw is also used for 
the 4th sample for APR -246 measurements ( Table 10; 3 hours after EOI)  
 
Table 11. PK Blood Sampling Timepoints for Venetoclax in Cycles 2 -5 
Venetoclax plasma collection ti mepoints  Day 4  
Prior to venetoclax administration a × 
 
8.5 Electrocardiographic Assessment  
Table 12 describes the routine ECG requirements from screening through Cycle 4:  
Table 12. ECG Assessment Requirements  
Time Point  ECG, number  Timing  
Baseline/Screening  Triplicate  Must be within 28 days of C1D1  
Cycle 1, Days 1 -4 Triplicate  Pre-dose; Post dose (6 hrs. after start of infusion; ± 
30 min)  
Cycles 2+, Day 1  Triplicate  Pre-dose  
 
If repeated QTcF measurements show a stable QTcF < 450 msec, or if QTcF remains stable 
within the interval of 450 –469 msec with no significant change at the EOI during several 
cycles of treatment, reducing the number of ECGs performed in the study may be discussed 
with the Medical Monitor.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 78 of 103 28 Octo ber 202 1 
Confidential - Entire Page  If a patient starts treatment with another medication known to prolong QT interval at any 
time during the study therapy, an additional pre - and post -dose (6 hours after start of 
infusion, ±30 min) ECG should be performed on the next treatment day.  
Please consult Section 6.3.1  for additional requirements for proceeding with treatment with 
APR-246.  
 
8.6 TP53  Testing  
Patients are enrolled based on the central lab result confirming at least one TP53  mutation 
not defined as benign or likely benign (see Laboratory Manual  for mutation algorithm ) in the 
bone marrow aspirate sample. The central peripheral blood sample may be  used for 
enrollment in the event a TP53 mutation is not detected in the bone marrow aspirate sample 
or if the bone marrow aspirate cannot be obtained due to a dry tap .  
If local TP53  mutation and/or p53 IHC results become available before central TP53  mutation 
results, enrollment may be made based on local results with Medical Monitor approval.  
 
9.0 STATISTICS  
Demographic data and disease -related characteristics will be summarized using descriptive 
statistics (count and percent, mean, median, standard deviation, minimum, maximum). 
Continuous variables will be presented by n, mean, median, standard deviation and range 
(minimum and maximum), and categorical variables will be presented by count and 
percentage of patients as appropriate. Data will be presented by each dose cohort in safety 
lead -in dose -finding portion and by each treatment arm and dose cohort in the expansion 
portion. All patient data, efficacy and safety data will be summarized.   
 
9.1 Sample Size  
This trial assumes a sample size of 12 –36 patients (6 –18 patients for each cohort) in the safety 
lead -in portion of the study and approximately 70 patients in the expansion portion of the 
study.  
In expansion cohorts 2 and 5, Simon’s two -stage “minimax” design will be used with alpha 
level of 0.05 and power of 80%. The null response rate will be set to 20% and the target 
response rate will be 40%. At the first stage if more than 4 responders in 18 patients 
observed, then the cohort will be continued to enroll another 15 patients in the second stage. 
A total of 11 responders or more in 33 patients will indicate the response rate is higher than 
the null response rate.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 79 of 103 28 Octo ber 202 1 
Confidential - Entire Page  9.2 Analysis Populations  
Safety population:  Patients will be evaluable for safety if they receive at least one dose of 
APR-246 with venetoclax and/or azacitidine. The safety population will be used to summarize 
exposure and safety parameters.  
 
DLT-evaluable population:  All patients who either experienced a DLT during first 4 weeks 
(Cycle 1) of the study treatment or received ≥80% of scheduled Cycle 1 dose of APR -246 in 
combination with venetoclax and/or azacitidine and did not experience a DLT. Any individual 
patient who is not evaluable for DLT will be replaced by a new patient through additional 
patient enrollment.  
 
Efficacy evaluable (EE) population:  All patients who complete at least one treatment cycle of 
APR-246 in combination with venetocl ax and/or azacitidine and who have at least one post -
treatment clinical response assessment. Patients who fail to complete one treatment cycle 
will also be considered EE if they show clear evidence of clinically significant disease 
progression. The EE popu lation will be the secondary analysis population for efficacy.  
 
Pharmacokinetics (PK) population:  Patients will be evaluable for pharmacokinetics if at least 
one post -dose sample for PK evaluation has been obtained.  
 
9.3 Endpoints  
9.3.1  Primary  
• DLTs, classified and graded according to the NCI CTCAE, version 5.0.  
• Frequency of treatment -emergent adverse events (TEAEs), and serious adverse events 
(SAEs) related to APR -246 in combination with venetoclax and/or azacitidine during 
the trial.  
• The RP2D of APR -246 (the dose a t which <2 out of 6 patients experience dose -limiting 
toxicity during the safety assessment period).  
 
9.3.2  Secondary  
1. CR rate, defined as the proportion of patients who achieve CR.  
2. CR + CRi rate, defined as the proportion of patients who achieve CR or CRi.  
3. CR + CRh rate, defined as the proportion of patients who achieve CR or CRh.  
4. ORR, defined as the proportion of patients achieving CR, CRi, CRp, PR and MLFS by the 
IWG 2003 AML criteria ( APPENDIX I ). The CRh rate will also be determined and is 
defined as bone marrow blasts <5%, ANC >0.5 × 109/L and platelets >50 × 109/L. 
5. OS, measured from the date of initiating study treatment to the date of death. Patients 
who have not died by the analysis data cut -off date will be censored at  their last date 
of contact.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 80 of 103 28 Octo ber 202 1 
Confidential - Entire Page  6. Rate of RBC and/or platelet TI for at least 56 days  
7. PFS, defined from the date of initiating study treatment to the date of disease 
progression per IWG 2003 AML criteria ( APPENDIX I ) or death as a result of any cause.  
8. Proportion of patients who transition to HSCT.  
9. Pharmacokinetic parameters: C max, AUC, V d and CL of APR -246 and Tmax, Cmax and AUC 
of venetoclax.  
 
9.3.3  Exploratory  
• Exploratory molecular analyses may include, but are not limited to: TP53  VAF by NGS, 
p53 IHC, mutations in other genes by NGS, RNA expression.  
 
9.4 Safety  
Safety data will be summarized for the safety population. These data will include AEs, ECGs 
and laborator y parameters. AE terms will be coded using the Medical Dictionary for Drug 
Regulatory Activities (MedDRA)®, version 22 or higher. AEs will be summarized by System 
Organ Class (SOC), preferred term, severity, and relationship to treatment. Serious adverse 
events, deaths, and AEs leading to dose modifications including early discontinuation of 
study treatment will be summarized. Laboratory parameters will be summarized by 
maximum NCI CTCAE version 5.0 severity grade and also by change from pre -treatment to 
scheduled time points using descriptive statistics. Laboratory parameter listings will include 
the normal ranges for each parameter. Each value will be classified as falling above, below, 
or within the normal range.  
 
Only AEs related to study screening proc edures are to be collected prior to the initiation of 
study treatment. Data summaries will include only treatment -emergent adverse events 
(TEAEs), defined as events occurring at the start of infusion on Day 1, Cycle 1 up to and 
including 30 days after last  dose.  
 
9.5 Efficacy  
CR will be summarized for all enrolled patients as the proportion of patients (%) with CR. In 
addition to presenting the CR rate, its associated exact 95% CI for each treatment arm will 
also be presented. CR rate will not be formally compa red between treatment arms.  
DoR will be defined as the time from the date when criteria for response are met to the date 
of PD or death due to any cause, whichever occurs first. Patients that are alive without 
relapse or progression will have their DOR cen sored at the date of the last clinical 
assessment. The duration of CR will be summarized in each treatment arm by providing 
DOCR and DOR, using Kaplan -Meier methodology. DoR endpoints will not be formally 
compared between treatment arms.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 81 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Overall response w ill be summarized in number (%) of patients in each category of responses 
and ORR will be analyzed by using the similar method as CR rate.  
Survival data will be collected at treatment and follow -up periods. Patients will be followed 
until death, or withdr awal of consent for study participation. OS is defined as the number of 
days from the date of enrollment to the date of death. Kaplan -Meier methodology will be 
utilized.  
PFS will be defined as the time from the date of enrollment to disease progression or death 
from AML whichever occurs first. If neither event occurs, PFS will be censored at the date of 
the last assessment. Kaplan -Meier methodology will be utilized.  
Transition rate to SCT will be analyzed using the similar methods as CR.  
 
9.6 Pharmacokinetic Analysis  
The pharmacokinetics of APR -246 and venetoclax will be summarized using descriptive 
statistics (mean, standard deviation, CV% mean, geometric mean, CV% geometric mean) and 
compared with historical control data.  
APR-246 and venetocl ax concentrations will be determined, and PK parameters (C max, Tmax, 
AUC, V d and CL) will be derived using population pharmacokinetic or non -compartmental 
methods.  
 
APR-246 concentrations will be determined by a validated high -performance liquid 
chromatography (HPLC) tandem mass spectrometry (LC/MS/MS) method. A population PK 
model will be used to estimate PK parameters C max, AUC and CL for each individual patient. 
APR-246 AUC and C max will then be tested for association with signs of efficacy and  safety in 
the presence of venetoclax. If an observable trend exists, a PK/PD model will be developed 
to evaluate the exposure -response relationship between APR -246 plasma exposure and 
outcome measures. Demographic and clinical data (ethnicity, current age , body weight, sex, 
disease status, etc.) will be utilized to assess interpatient variability in the PK and PK/PD 
relationships.  
 
APR-246 PK parameters will be compared to historical controls for the assessment of drug -
drug interactions.  
 
9.7 Exploratory analy ses 
Descriptive statistics/results from exploratory molecular analyses will be written and may 
include, but are not limited to: TP53 VAF by NGS, p53 IHC, mutations in other genes by NGS, 
RNA expression. Please consult Laboratory Manual regarding details on  the exploratory 
biomarker sample processin g. 
 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 82 of 103 28 Octo ber 202 1 
Confidential - Entire Page  10.0 QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES  
10.1 Monitoring of the Study and Regulatory Compliance  
The project manager, or designee, will make an initiation site visit to each institution to 
review the protoc ol and its requirements with the Investigator(s), inspect the drug storage 
area, fully inform the Investigator of his/her responsibilities and the procedures for assuring 
adequate and correct documentation. During the initiation site visit the CRFs will be  
reviewed. Other pertinent study materials will also be reviewed with the Investigator’s 
research staff. During the course of the study, the monitor will make regular site visits in 
order to review protocol compliance, examine CRFs and individual patient’s  medical records 
and assure that the study is being conducted according to pertinent regulatory 
requirements. All CRF entries will be verified with source documentation. The review of 
medical records will be done in a manner to assure that patient confiden tiality is maintained.  
 
10.2 Curricula Vitae and Financial Disclosure of Investigators  
All Principal Investigators will be required to provide a current signed and dated curriculum 
vitae, a completed FDA Form 1572 and a financial disclosure statement to Spons or’s 
monitoring CRO. All Sub -Investigators will be required to provide a current curriculum vitae 
and a financial disclosure statement to Sponsor’s monitoring CRO.  
 
10.3 Protocol Modifications  
No modification of the protocol should be implemented without the pr ior written approval 
of the Sponsor or the Sponsor’s representative. Any such changes which may affect a 
patient’s treatment or informed consent, especially those increasing potential risks, must 
receive prior approval by the IRB/IEC. The exception to this  is where modifications are 
necessary to eliminate an immediate hazard to trial patients, or when the change involves 
only logistical or administrative aspects of the trial (e.g., change in monitor, change in 
telephone number). Other administrative revisio ns which may impact the clinical portion of 
a study will be duly reported to the IRB/IEC by the Principal Investigator.  
 
10.4 Publication Policy  
The publication of the results of the study will be subject to the terms and conditions of the 
clinical trial agreement between the Sponsor and Investigators. Sponsor approval is required 
for publication of any data from this trial.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 83 of 103 28 Octo ber 202 1 
Confidential - Entire Page  11.0 ETHICAL CONSIDERATION S 
11.1 Informed Consent  
The Investigator will obtain written informed consent from each patient, or their authorized 
representative, participating in the study. The form must be signed, witnessed and dated. 
The informed consent form will contain all the Essential Elements of Info rmed Consent set 
forth in 21  CFR, Part 50, the European Union Directive 2001/20/EC and its associated Detailed 
Guidances, European Union GCP Directive 2005/28/EC, the ICH Guideline for GCP, 
Section  4.8, and the terms of the Declaration of Helsinki (2013). Copies of the signed 
document should be given to the patient and filed in the Investigator’s study file, as well as 
the patient’s medical record if in conformance with the institution’s Standard Operating 
Procedures.  
 
11.2 Institutional Review Board/Independen t Ethics Committee  
The study will not be initiated without approval of the appropriate IRB/IEC and compliance 
with all administrative requirements of the governing body of the institution. This protocol, 
consent procedures, and any amendments must be appro ved by the IRB/IEC in compliance 
with current regulations of the FDA and the European Union as applicable and in accordance 
with ICH/GCPs. A letter of approval will be sent to the Sponsor prior to initiation of the study 
and when any subsequent modificatio ns are made. The IRB/IEC will be kept informed by the 
Investigator, Sponsor’s monitoring CRO or the Sponsor, as required by national regulations, 
as to the progress of the study as well as to any serious and unexpected AEs.  
 
11.3 Patient Privacy  
In order to m aintain patient confidentiality, all CRFs, study reports and communications 
relating to the study will identify patients by initials and assigned patient numbers; patients 
should not be identified by name. In accordance with local, national or federal regu lations, 
the Investigator will allow the Sponsor or designee personnel access to all pertinent medical 
records in order to verify the data gathered on the CRFs and to audit the data collection 
process. Regulatory agencies such as the U.S. FDA may also requ est access to all study 
records, including source documentation for inspection. Clinical information will not be 
released without the written permission of the patient as outlined in the patient consent 
form.  
 
12.0 DATA HANDLING AND RECORD KEEPING  
12.1 Data to be En tered Directly in the Case Report Form  
The CRF will be the source record.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 84 of 103 28 Octo ber 202 1 
Confidential - Entire Page  12.2 Recording of Data  
Data collected during the study will be entered in the patient’s CRF by the investigational site 
staff. The staff will keep records of the patient’s visit in the f iles considered as source 
documents for the site, e.g., hospital chart, research chart. The Investigator will be 
responsible for the recording of all data on the CRF and for submitting the data to the 
Sponsor or their designee in a timely manner. Should an y value be significantly different 
from normal, the Investigator will comment in the appropriate sections provided in the  CRF.  
 
The Investigator will provide access to his/her original records to permit a representative 
from the Sponsor to verify the prop er transcription of data. To facilitate photocopying, 
entries must be recorded legibly in black ink only. Erroneous entries will be crossed out with 
a single line, so as to remain legible. The correct value will be entered above the error  and 
then initiale d and dated by the person authorized to make the correction.  
 
12.3 Study Records  
U.S. Federal laws require that an Investigator maintain all study records for the indication 
under investigation for two years following the date a Product Licensing Application is  
approved or, if no application is to be filed or if the application is not approved for such 
indication, until two years after the investigation is discontinued and the FDA is notified.  
 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 85 of 103 28 Octo ber 202 1 
Confidential - Entire Page  13.0 REFERENCES  
1.  Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by 
subtype and demographic characteristics, 1997 –2002. Cancer Causes Control . 
2008;19(4):379 -390. doi:10.1007/s10552 -007-9097 -2 
2.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin . 2019;69(1):7 -34. 
doi:10.3322/caac.21551  
3.  Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in 
Europe by morphologic subtype: results of the HAEMACARE project. Blood . 
2010;116(19):3724 -3734. doi:10.1182/blood -2010 -05-282632  
4.  Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological 
malignancy by sub -type: a report from the Haematological Malignancy Research 
Network. Br J Cancer . 2011;105(11):1684 -1692. doi:10.1038/bjc.2011.450  
5.  Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myel oid leukaemia 
revealed by whole -genome sequencing. Nature . 2012;481(7382):506 -510. 
doi:10.1038/nature10738  
6.  Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the 
TP53 gene in acute myeloid leukemia are strongly associated  with a complex 
aberrant karyotype. Leukemia . 2008;22(8):1539 -1541. doi:10.1038/leu.2008.143  
7.  De Kouchkovsky I, Abdul -Hay M. ‘Acute myeloid leukemia: a comprehensive review 
and 2016 update.’ Blood Cancer J . 2016;6(7):e441 -e441. doi:10.1038/bcj.2016.50  
8.  Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR -29b predictive 
significance in older AML patients treated with a 10 -day schedule of decitabine. Proc 
Natl Acad Sci . 2010;107(16):7473 -7478. doi:10.1073/pnas.1002650107  
9.  Quintas -Cardama A , Ravandi F, Liu -Dumlao T, et al. Epigenetic therapy is associated 
with similar survival compared with intensive chemotherapy in older patients with 
newly diagnosed acute myeloid leukemia. Blood . 2012;120(24):4840 -4845. 
doi:10.1182/blood -2012 -06-436055  
10.  Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute 
myeloid leukemia. Hematology . 2014;2014(1):8 -13. doi:10.1182/asheducation -
2014.1.8  
11.  Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients  with 
acute myeloid leukemia. Cancer . 2012;118(4):1014 -1022. doi:10.1002/cncr.26354  
12.  DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 86 of 103 28 Octo ber 202 1 
Confidential - Entire Page  azacitidine in treatment -naive, elderly patients with acute myeloid leukemia. Blood . 
2019;133(1):7 -17. doi:10.1182/BLOOD -2018 -08-868752  
13.  Wei AH, Strickland SA, Hou J -Z, et al. Venetoclax Combined With Low -Dose Cytarabine 
for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a 
Phase Ib/II Study. J Clin Oncol . 2019;37 (15):1277 -1284. doi:10.1200/JCO.18.01600  
14.  DiNardo CD, Pollyea DA, Jonas BA, et al. Updated Safety and Efficacy of Venetoclax 
with Decitabine or Azacitidine in Treatment -Naive, Elderly Patients with Acute 
Myeloid Leukemia. Blood . 2017;130(Suppl 1). 
http://www.bloodjournal.org/content/130/Suppl_1/2628?sso -checked=true. Accessed 
July 12, 2019.  
15.  Kim MP, Zhang Y, Lozano G. Mutant p53: Multiple Mechanisms Define Biologic 
Activity in Cancer. Front Oncol . 2015;5:249. doi:10.3389/fonc.2015.00249  
16.  Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor 
suppressor -DNA complex: understanding tumorigenic mutations. Science . 
1994;265(5170):346 -355. http://www.ncbi.nlm.nih.gov/pubmed/8023157. Accessed 
June 12, 2019.  
17.  Li R, Sutphin PD, Sc hwartz D, et al. Mutant p53 protein expression interferes with 
p53-independent apoptotic pathways. Oncogene . 1998;16(25):3269 -3277. 
doi:10.1038/sj.onc.1201867  
18.  Kim MP, Zhang Y, Lozano G. Mutant p53: Multiple Mechanisms Define Biologic 
Activity in Cance r. Front Oncol . 2015;5:249. doi:10.3389/fonc.2015.00249  
19.  Ok CY, Patel KP, Garcia -Manero G, et al. Mutational profiling of therapy -related 
myelodysplastic syndromes and acute myeloid leukemia by next generation 
sequencing, a comparison with de novo dise ases. Leuk Res . 2015;39(3):348 -354. 
doi:10.1016/j.leukres.2014.12.006  
20.  Pedersen -Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of 
therapy -related myelodysplasia and acute myeloid leukemia. Leukemia . 
2008;22(2):240 -248. doi:10.1038/sj. leu.2405078  
21.  Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute 
myeloid leukemia with a complex aberrant karyotype is a distinct biological entity 
characterized by genomic imbalances and a specific gene expression profile. Gene s, 
Chromosom Cancer . 2005;43(3):227 -238. doi:10.1002/gcc.20193  
22.  Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia 
with complex karyotype correlate with specific copy number alterations, monosomal 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 87 of 103 28 Octo ber 202 1 
Confidential - Entire Page  karyotype, and disma l outcome. Blood . 2012;119(9):2114 -2121. doi:10.1182/blood -
2011 -08-375758  
23.  Hou H -A, Chou W -C, Kuo Y -Y, et al. TP53 mutations in de novo acute myeloid 
leukemia patients: longitudinal follow -ups show the mutation is stable during 
disease evolution. Blood Cancer J . 2015;5(7):e331 -e331. doi:10.1038/bcj.2015.59  
24.  Bowen D, Groves MJ , Burnett AK, et al. TP53 gene mutation is frequent in patients 
with acute myeloid leukemia and complex karyotype, and is associated with very 
poor prognosis. Leukemia . 2009;23(1):203 -206. doi:10.1038/leu.2008.173  
25.  Song H, Hollstein M, Xu Y. p53 gain -of-function cancer mutants induce genetic 
instability by inactivating ATM. Nat Cell Biol . 2007;9(5):573 -580. doi:10.1038/ncb1571  
26.  Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of 
the guardian of the genome. Cancer Res . 2000;60(24):6788 -6793. 
http://www.ncbi.nlm.nih.gov/pubmed/11156366. Accessed June 12, 2019.  
27.  Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients 
with acute myeloid leukemia and complex k aryotype, and is associated with very 
poor prognosis. Leukemia . 2009;23(1):203 -206. doi:10.1038/leu.2008.173  
28.  Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and 
evolution of therapy -related acute myeloid leukaemia. Nature . 2015;518(7540):552 -
555. doi:10.1038/nature13968  
29.  Yanada M, Yamamoto Y, Iba S, et al. TP53 mutations in older adults with acute 
myeloid leukemia. Int J Hematol . 2016;103(4):429 -435. doi:10.1007/s12185 -016-1942 -
1 
30.  Seifert H, Mohr B, Thiede C, et al. T he prognostic impact of 17p (p53) deletion in 2272 
adults with acute myeloid leukemia. Leukemia . 2009;23(4):656 -663. 
doi:10.1038/leu.2008.375  
31.  Parkin B, Erba H, Ouillette P, et al. Acquired genomic copy number aberrations and 
survival in adult acute my elogenous leukemia. Blood . 2010;116(23):4958 -4967. 
doi:10.1182/blood -2010 -01-266999  
32.  Nakano Y, Naoe T, Kiyoi H, et al. Prognostic value of p53 gene mutations and the 
product expression in de novo acute myeloid leukemia. Eur J Haematol . 
2000;65(1):23 -31. http://www.ncbi.nlm.nih.gov/pubmed/10914936. Accessed June 12, 
2019.  
33.  Bories C. A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, 
and Personalized Treatment Selection. In: American Society of Hematology Annual 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 88 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Meeting 2018 . ; 2018.  
34.  Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival 
in older patients with acute myeloid leukemia treated with azacitidine or 
conventional care. Leukemia . 2018;32(12):2546 -2557. doi:10.1038/s41375 -018-0257 -z 
35.  DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2 -inhibitor 
venetoclax in combination therapy for relapsed and refractory acute myeloid 
leukemia and related myeloid malignancies. Am J Hematol . 2018;93(3):401 -407. 
doi:10.1002/ajh. 25000  
36.  Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy 
metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. 
Nat Med . 2018;24(12):1859 -1866. doi:10.1038/s41591 -018-0233 -1 
37.  Venetocla x. Highlights of Prescribing Information. Updated 5/2020 .; 2020. 
www.fda.gov/medwatch. Accessed September 17, 2020.  
38.  Bogenberger JM, Delman D, Hansen N, et al. Ex vivo activity of BCL -2 family inhibitors 
ABT-199 and ABT -737 combined with 5 -azacytidine in myeloid malignancies. Leuk 
Lymphoma . 2015;56(1):226 -229. doi:10.3109/10428194.2014.910657  
39.  Metzeler KH, Herold T, Rothenberg -Thurley M, et al. Spectrum and prognostic 
relevance of driver gene mutations in acute myeloid leukemia. Blood . 
2016;128(5):6 86-698. doi:10.1182/blood -2016 -01-693879  
40.  Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid 
leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II 
study. Leuk Lymphoma . 2012;53(1):110 -117. doi:10.3109/10428194.2011.606382  
41.  Lehmann S, Bykov VJN, Ali D, et al. Targeting p53 in Vivo: A First -in-Human Study With 
p53-Targeting Compound APR -246 in Refractory Hematologic Malignancies and 
Prostate Cancer. J Clin Oncol . 2012;30(29):3633 -3639. doi :10.1200/JCO.2011.40.7783  
42.  European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity 
analysis in clinical trials to the guideline on statistical principles for clinical trials - 
Step 2b. 2017;44(August):1 -23. 
43.  Deneberg S, Cherif H, Lazarevic V, et al. An open -label phase I dose -finding study of 
APR-246 in hematological malignancies. Blood Cancer J . 2016;6(7):e447. 
doi:10.1038/bcj.2016.60  
44.  Sallman DA, DeZern A, Sweet K, et al. Abstract CT068: Phase Ib/II comb ination study 
of APR -246 and azacitidine (AZA) in patients with &lt;em&gt;TP53&lt;/em&gt; mutant 
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Cancer Res . 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 89 of 103 28 Octo ber 202 1 
Confidential - Entire Page  2018;78(13 Supplement):CT068 LP -CT068. doi:10.1158/1538 -7445.AM2018 -CT068  
45.  Sallman D, DeZern A, Garcia ‐Manero G, Steensma DP, Roboz GJ. Phase 2 Results of 
APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic 
Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). In: ; 2019.  
46.  Fenaux P, Steensma DP, Van Eygen K. Treatment with Imetelstat Provides Durable 
Transfusion Independence in Heavily Transfused Non -Del(5q) Lower Risk MDS 
Relapsed/Refractory to Erythropoiesis -Stimulating Agents. In: ; 2019.  
47.  VIDAZA (azacitidine for injection), Highlights of P rescribing Information. 2018.  
48.  FDA, CDER. Venetoclax Prescribing Information . www.fda.gov/medwatch. Accessed 
June 24, 2019.  
49.  Aprea Therapeutics. APR -246 Investigator’s Brochure v10.1. 2019:168.  
50.  NCCN. NCCN Clinical Practice Guidelines in Oncolo gy for Chronic Myeloid Leukemia.  
Version 3.; 2020.  
51.  Lancet JE, Uy GL, Cortes JE, et al. Cpx -351 (cytarabine and daunorubicin) liposome for 
injection versus conventional cytarabine plus daunorubicin in older patients with 
newly diagnosed secondary acute  myeloid leukemia. In: Journal of Clinical Oncology . 
Vol 36. American Society of Clinical Oncology; 2018:2684 -2692. 
doi:10.1200/JCO.2017.77.6112  
52.  Lindsley RC. Genetic characteristics and outcomes by mutation status in a phase 3 
study of CPX -351 versus 7+3 in older adults with newly diagnosed, high -
risk/secondary acute myeloid leukemia. 2019 ASH Annual Meeting & Exposition. 
Abstract 15. In: ; 2019.  
53.  DiNardo CD. European Hematology Association Annual Congress. In: ; 2020.  
54.  Cluzeau T. Europe an Hematology Association Annual Congress. In: ; 2020.  
55.  FDA. Venetoclax Prescribing Information .; 2016. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf.  
56.  FDA. Azacitidine Prescribing Information .; 2018.  
57.  Roselló S, Bl asco I, García Fabregat L, Cervantes A, Jordan K, ESMO Guidelines 
Committee. Management of infusion reactions to systemic anticancer therapy: ESMO 
Clinical Practice Guidelines†. Ann Oncol . 2017;28(suppl_4):iv100 -iv118. 
doi:10.1093/annonc/mdx216  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 90 of 103 28 Octo ber 202 1 
Confidential - Entire Page  58.  Azacit idine. Highlights of Prescribing Information .; 2020. www.fda.gov/medwatch. 
Accessed September 23, 2020.  
59.  Cheson BD, Bennett JM, Kopecky KJ, et al. Revised Recommendations of the 
International Working Group for Diagnosis, Standardization of Response Cri teria, 
Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute 
Myeloid Leukemia. J Clin Oncol . 2003;21(24):4642 -4649. doi:10.1200/JCO.2003.04.036  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 91 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX I – Response Criteria Based on Modified Recommendations of the 
International Working Group for Diagnosis, Standardization of Response 
Criteria, Treatment Outcomes, and Reporting Standards in Acute Myeloid 
Leukemia59 
 
Response Criterion  Neutrophils, 
×109/L Platelets,  
×109/L Bone Marrow Aspirate Blasts (%) (by 
biopsy acceptable if as pirate not 
available)  
CR  >1.0  >100  <5 
CRi ANC ≥1,000 OR platelets 
≥100,000  <5 
MLFS  NA NA <5 
PR >1.0  >100  >50% decrease from baseline to level 
of 5-25%  
SD (for patients 
without a prior best 
response of CR, CRi , 
MLFS, or PR ) Absence of CR, CRi, PR, MLFS; and criteria for PD  not met  
Hematologic 
relapse (for patients 
with a prior best 
response of CR, CRi , 
MLFS ) Bone marrow blasts ≥5%, or reappearance of bla sts in the  
blood , on two consecutive assessments separated by ≥28 days. 
Development of new extramedullary disease.  
PD (for patients 
with a prior best 
response of SD or 
PR) Evidence for an increase in bone marrow blast percentage  and/or increase 
of absolut e blast counts in the blood , on two consecutive assessments at 
least 28 days apart:  
 
>50% increase in marrow blasts over baseline (a minimum  15% point 
increase is required in cases with <30% blasts at  baseline; or persistent 
marrow blast percentage of >70%  over at least 3 mo nths ; without at least a 
100% improvement in  
ANC to an absolute level ( >0.5 × 109/L [500/mL], and/or  platelet count to 
>50 × 109/L [50 ,000/mL] non -transfused); or  
 
>50% increase in peripheral blasts (WBC × % blasts) to  >25 × 109/L 
(>25,000/mL) (in the absence of differentiation  syndrome); or  
 
New extramedullary disease  
 
Additional Responses to be Assessed in Addition to Above Responses  
These responses in addition to other responses and do not have specific hematologic criteria.  
 
Cytogenetic CR  Normal karyotype in a patient with abnormal cytogenetics at baseline.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 92 of 103 28 Octo ber 202 1 
Confidential - Entire Page  TP53  Molecular CR  TP53  mutation not detected by NGS based on local testing in a patient with 
detectible TP53  VAF by NGS at baseline.  
 
Additional Responses to be Assessed in Addition to Above Responses  
These responses in addition to other responses and do not have specific hema tologic criteria.  
 
Cytogenetic CR  Cytogenetic CR  
TP53  Molecular CR  TP53  Molecular CR  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 93 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX II - Cockcroft -Gault Equation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Males:    
Creatinine CL 
(mL/min)  =   Weight (kg) × (140 – Age)  
72 × serum creatinine (mg/dL)  
Females:    
Creatinine CL 
(mL/min)  =    Weight (kg) × (140 – Age)  × 0.85  
72 × serum creatinine (mg/dL)  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 94 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX III - ECOG Performance Status  
 
 
 
       Grade  
 
 
0  
Fully active, able to carry on all pre -disease performance without 
restriction.  
 
 
1  
Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
housework, office work.  
 
 
2  
Ambulatory and capable of all self -care but unable to carry out 
any work activities. Up and about more than 50% of waking 
hours.  
 
 
3  
Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours.  
 
 
4  
Completely disabled. Cannot carry on any self -care. Totally 
confined to bed or chair.  
 
 
5  
Dead.  
 
 
 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 95 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX IV - Acceptable Contraceptive Methods  
● Male or female condom with or without spermicide  
● Cervical cap, diaphragm or sponge with spermicide  
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of <1% per year when used consistently and correctly.  
● Combined (estrogen - and progesterone -containing) hormonal contraception b 
○ Oral  
○ Intravaginal  
○ Transdermal  
○ Injectable  
● Progestogen -only hormonal contraception b 
○ Oral  
○ Injectable  
Highly Effective Methods That Have Low User Dependency  
Failure rate of <1% per year when used consistently and correctly.  
● Progesterone -only contraceptive implant b, c  
● Intrauterine hormone -releasing system (IUS)  b  
● Intrauterine device (IUD)  
● Bilateral tubal occlusion  
● Vasectom y  
Vasectom y is a highly effective contraception method provided that the partner is the 
sole male sexual partner of the female of childbearing potential and the absence of 
sperm has been confirmed. If not, an additional highly effective method of contraception 
should  be used.  
● Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatment. The reliability of sexual abstinenc e needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant.)  
Notes:  
Use should be consistent with local regulations regarding the use of contraceptive 
methods for participants of clinical studies.  
a) Typical use failure rates are lower than perfect -use failure rates (i.e., when used 
consistently and correctly).  
b) If hormonal contraception efficacy is potentially decreased due to interaction with 
study treatment, condoms must be used in addition to the hormonal contraception 
during the treatment period and for at least 120 days, (corresponding to time needed to 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 96 of 103 28 Octo ber 202 1 
Confidential - Entire Page  eliminate study treatment plus 30 days for study treatments with genotoxic potential) 
after the last dose of the study tr eatment.  
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, 
acceptable hormonal contraceptives are limited to those which inhibit ovulation .  
 
 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 97 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX V - New Yo rk Heart Association (NYHA) Classification  
 
NYHA Grading  MET*  
Class I  No limitations. Ordinary physical activity does not 
cause undue fatigue, dyspnea or palpitations 
(asymptomatic LV dysfunction)  >7 
Class II  Slight limitation of physical activity. Ordinary physical 
activity results in fatigue, palpitation, dyspnea or 
angina pectoris (mild Congestive Heart Failure (CHF)).  5 
Class III  Marked limitation of physical activity. Less than 
ordinary physical activity leads to symptoms 
(moderate CHF)  2 – 3 
Class IV  Unable to carry on any physical activity without 
discomfort. Symptoms of CHF present at rest (severe 
CHF).  1.6 
 
*MET (metabolic equivalent) is defined as the resting VO 2 for a 40 -year -old 70kg man.  
1 MET = 3.5 mL O 2/min/kg body weight.  
 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 98 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX VI - Study Drug Diaries  
 
VENETOCLAX DRUG DIARY  
 
Instructions :  
You will use this diary to record each dose of venetoclax that you take. You should also use 
this diary to record any side effects that you experience and medications that you take other 
than the venetoclax. Please be sure to bring this diary with you to your next clinic visit.  
 
Venetoclax:  
• Venetoclax  is taken once a day every day, approximately 24 hours apart.  
• Venetocla x should be taken with food. On days 1 – 4 of cycle 1 it is recommended that 
venetoclax is taken approximately one hour after start of APR -246 infusion. Starting 
at cycle 2 venetoclax can be taken before or after start of APR -246 infusion (± 2 hours).  
• If you forget to take a dose of venetoclax  and it is within 12 hours of when it should 
have been taken, you should take the dose. If it has been more than 12 hours, you 
should skip that dose and take the next dose at the next regular time.  
• If you vomit after taking a dose of venetoclax , you should not make up the dose or 
take additional pills, you should take the next dose at the next regular time.  
• Always bring your pill bottles (including those that are empty) and your diary with you 
to each clinic visit.   
 
If you have any questions, please ask a study team member or your doctor.  
 
 
 
 Patient Number:   __________  
 Patient Initials:   __________  
 Cycle Number:  _______  
Start Date: _______________  
 
Venetoclax  tablets to take at each dose:  100 mg = _____  
       
 
Other information/Comments:  
            
             STUDY STAFF USE ONLY  
 
Staff member reviewing diary at end of study 
cycle:  
 
 
      
Staff initials   Date reviewed  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 99 of 103 28 Octo ber 202 1 
Confidential - Entire Page  VENETOCLAX DRUG DIARY  (continued)  
 
Patient Number/Initials:  ____________________   Cycle:  _____  
 
Cycle 
Day Date Taken  Time 
Taken  Number of 
100mg 
venetoclax 
tablets 
taken  Comments  
(Side effects, complaints, other 
medications)  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
20     
21     
22     
23     
24     
25     
26     
27     
28     
 
* NOTE : Add additional days in case needed due to scheduling delay or dose modifications.  
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 100 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX VII - Patient Handout: Prohibited Medications (For Patients Enrolled 
in Cohorts with Venetoclax)  
PROHIBITED MEDICATIONS   
 
One of the medications you are receiving during this clinical trial, venetoclax, interacts with 
some drugs that are processed by your liver. Because of this, it is very important to tell your 
study doctors about all of your medicine before you start this s tudy. It is also very important 
to tell them if you stop taking any regular medicine, or if you start taking a new medicine 
while you take part in this study. When you talk about your medicine with your study doctor, 
include medicine you buy without a pres cription at the drug store (over -the counter remedy), 
or anything that you buy from the health food store or grocery store (herbal supplement). 
Many health care prescribers can write prescriptions. You must also tell your other 
prescribers (doctors, physic ians’ assistants or nurse practitioners) that you are taking part in 
a clinical trial.  
 
Bring this paper  with you .  
 
• Venetoclax is processed by a certain enzyme in the liver called CYP3A4. Drugs that 
increase the activity of this enzyme are called “induce rs”, and drugs that decrease 
the activity of this enzyme are called “inhibitors”. Venetoclax must be used very 
carefully with other medicines that are inducers or inhibitors of CYP3A4. Venetoclax 
may also interact with other drugs that are processed by the  liver.  
• You and healthcare providers who prescribe drugs for you must be careful about 
adding or removing any drug in this category.  
Before you start the study, your study doctor will work with your regular prescriber to switch 
the following medications if  you are taking them:  
 
Avoid strong CYP3A inhibitors,  i.e. clarithromycin, indinavir, itraconazole, ketoconazole, 
lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, 
telithromycin, and voriconazole. Avoid grapefru its and grapefruit juice. If a strong CYP3A 
inhibitor must be coadministered, the dose of venetoclax should be reduced. If the strong 
inhibitor is discontinued, the dose of venetoclax should be increased (after 3 to 5 half -lives 
of the inhibitor) to the do se used prior to initiation of the strong inhibitor.  
 
Avoid strong CYP3A inducers,  i.e. phenytoin, rifampin, enzalutamide, and St John’s wort.  
 
Avoid P -gp inhibitors,  i.e. amiodarone, carvedilol, clarithromycin, dronedarone, itraconazole, 
lapatinib, lopina vir and ritonavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir 
and ritonavir, telaprevir, tipranavir and ritonavir, verapamil.  
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 101 of 103 28 Octo ber 202 1 
Confidential - Entire Page  Avoid P -gp substrates with narrow therapeutic index,  i.e. amitriptyline, carbamazepine, 
clonidine, ciclosporin, di gitoxin, digoxin, imipramine, phenobarbital, phenytoin, quinidine.  
 
Your regular prescribers should look at these websites: https://www.crediblemeds.org  
http://medicine.iupui.edu/clinpharm/ddis/table.asp  to see if any medicine they want to 
prescribe is on a list of drugs to avoid. Your study doctor may also have a list of medications 
for you to show your regular prescribers instead of, or in addit ion to, this website.   
 
Eating grapefruit, grapefruit containing products, Seville oranges (including marmalade 
made with Seville oranges), and starfruit is prohibited while you are taking venetoclax as 
these may increase the amount of venetoclax in your blood.  Please discuss any questio ns 
about prohibited foods with your study doctor.  
 
Other medicines can be a problem with your study drugs.  
o You should check with your doctor or pharmacist whenever you need to use an over -the-
counter medicine or herbal supplement.  
o Your regular prescriber should check a medical reference or call your study doctor before 
prescribing any new medicine for you. Your study doctor’s name is _______________ and he 
or she can be contacted at _______________________.  
 
 
 
 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 102 of 103 28 Octo ber 202 1 
Confidential - Entire Page  APPENDIX VIII - Dose Modifications for Use with CYP3A and P -gp Inhibitors  
Concomitant use of venetoclax with strong  CYP3A inhibitors at initiation and during ramp -
up phase is contraindicated. Concomitant use of venetoclax with strong CYP3A inhibitors 
increases venetoclax exposure (i.e., C max and AUC) and may increase the risk for TLS at 
initiation and during ramp -up phase. For patients who have completed the ramp -up 
phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 
75% when strong  CYP3A inhibitors must be used concomitantly.  
 
Avoid concomitant use of venetoclax with moderate  CYP3A inhibitors or P -gp inhibitors. 
Consider alternative treatments. If a moderate CYP3A inhibitor or a P -gp inhibitor must 
be used, reduce th e venetoclax dose by at least 50%. Monitor these patients more closely 
for signs of toxicities.  
 
Resume the venetoclax dose that was used prior to initiating the CYP3A inhibitor or P -gp 
inhibitor 2 to 3 days after discontinuation of the inhibitor.  
 
The r ecommendations for managing drug -drug interactions are summarized in the table 
below.  
 
Co-administered drug  Initiation and Ramp -Up 
Phase  Steady Daily Dose (After 
Ramp -Up Phase)  
Posaconazole  Day 1 – 10 mg  
Day 2 – 20 mg  
Day 3 – 50 mg  
Day 4 – 70 mg  Reduce venetoclax dose to 
70 mg.  
Other strong CYP3A 
inhibitor  Day 1 – 10 mg  
Day 2 – 20 mg  
Day 3 – 50 mg  
Day 4 – 100 mg  Reduce venetoclax dose to 
100 mg.  
Moderate CYP3A inhibitor  Reduce the venetoclax dose by at least 50%  
P-gp inhibitor  
 
Warfarin  
Concomitant use of venetoclax increases warfarin C max and AUC inf, which may increase the 
risk of bleeding. Closely monitor international normalized ratio (INR) in patients using 
warfarin concomitantly with venetoclax.  
 
P-gp Substrates  
Concomitant use of venetoclax increases C max and AUCinf of P -gp substrates, which may 
increase toxicities of these substrates. Avoid concomitant use of venetoclax with a P -gp 
Aprea Therapeutics  
Protocol Number A19 -11184   A Phase I Study of APR -246 in Combination 
with Venetoclax and/or Azacitidine in AML  
 
1184_CSP 5.0 103 of 103 28 Octo ber 202 1 
Confidential - Entire Page  substrate. If a concomitant use is unavoidable, separate dosing of the P -gp substrate at 
least 6 hours before venetoclax.  
 
Please refer to the venetoclax USPI37 for additional details on drug -drug interactions.  
 
Below ( Table 13) are examples of CYP3A inhibitors and inducers (strong and moderate); 
however, this is not an exhaustive list.   
 
 
Table 13. CYP3A Inhibitors and Inducers 1 
CYP3A Inhibitors  
Strong CYP3A Inhibitors  Moderate CYP3A Inhibitors  
boceprevir, cobicistat, danoprevir and 
ritonavir, elvitegravir and ritonavir, 
indinavir and ritonavir, itraconazole, 
ketoconazole, lopinavir and ritonavir, 
paritaprevir and ritonavir and (ombit asvir 
and/or dasabuvir), posaconazole, 
ritonavir, saquinavir and ritonavir, 
telaprevir, tipranavir and ritonavir, 
telithromycin, troleandomycin, 
voriconazole  aprepitant, ciprofloxacin, conivaptan, 
crizotinib, cyclosporine, diltiazem, 
dronedarone, erythromy cin, fluconazole, 
fluvoxamine, imatinib, tofisopam, 
verapamil  
 
CYP3A Inducers  
Strong CYP3A Inducers  Moderate CYP3A Inducers  
apalutamide, carbamazepine, 
enzalutamide, mitotane, phenytoin, 
rifampin, St. John’s wort   bosentan, efavirenz, etravirine, 
phenobarbital, primidone  
Note: In addition to the medications listed above, patients taking venetoclax should not 
consume grapefruit, grapefruit products, Seville oranges, (including marmalade containing 
Seville oranges), or star fruit.  
 
 
 
 